

**Attachment 1**  
**Meeting Transcript**

# **Official Transcript of Proceedings**

## **NUCLEAR REGULATORY COMMISSION**

**Title:** Integration of Case Studies in the Use of Risk Information in the Nuclear Materials and Waste Regulatory Process - Public Meeting

**Docket Number:** (not applicable)

**Location:** Rockville, Maryland

**Date:** Thursday, October 25, 2001

**Work Order No.:** NRC-080

**Pages 1-142**

**NEAL R. GROSS AND CO., INC.  
Court Reporters and Transcribers  
1323 Rhode Island Avenue, N.W.**

**Washington, D.C. 20005**  
**(202) 234-4433**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

UNITED STATES OF AMERICA

NUCLEAR REGULATORY COMMISSION

+ + + + +

INTEGRATION OF CASE STUDIES IN THE USE OF RISK  
INFORMATION IN THE NUCLEAR MATERIALS AND WASTE

REGULATORY PROCESS - PUBLIC MEETING

+ + + + +

THURSDAY, OCTOBER 25, 2001

+ + + + +

ROCKVILLE, MARYLAND

+ + + + +

The meeting commenced at 9:00 a.m., the  
Auditorium of 11545 White Flint North, Rockville,  
Maryland, Dr. Patricia Rathburn, Facilitator.

PANEL:

LAWRENCE KOKAJKO

DR. MARGARET FEDERLINE

MARISSA BAILEY

DENNIS DAMON

RAEANN SHANE

JAMES SMITH

DR. JAMES DANNA

DR. ROBERT BARI

VINOD MUBAYI

DR. PATRICIA RATHBUN, Facilitator

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

A-G-E-N-D-A

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

PAGE

Opening remarks - Lawrence Kokajko . . . . . 3

Risk-Informing Nuclear Materials and  
Waste Safety - Margaret Federline . . . . . 10

Insights from Case Studies

- Overview - Marissa Bailey . . . . . 16
- Screening Considerations - Raeann Shane 25
- Safety Goals

  - Dennis Damon . . . . . 31
  - Robert Bari . . . . . 38

- Process Improvements - Jim Smith . . . . . 51
- Where we go from here - Jim Danna . . . . . 58

Feedback Session . . . . . 67

Closing remarks - Lawrence Kokajko . . . . . 139

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

P-R-O-C-E-E-D-I-N-G-S

(9:10 a.m.)

1  
2  
3 MR. KOKAJKO: Good morning, and welcome to  
4 our meeting this morning on the Integration of our  
5 Case Studies. I see some new faces in the audience  
6 this morning, and I appreciate your being here today.  
7 I also see some of our old attendees, and I thank you  
8 for coming back. I would like to welcome you to this  
9 meeting and thank you for wanting to participate  
10 today.

11 Before I get to the specifics of today's  
12 meeting, let me provide some background of why we are  
13 here. The NRC is focused on safety, and we view the  
14 use of risk information assessment and management  
15 techniques and strategies as tools to help us achieve  
16 our goal of maintaining our focus on safety, and being  
17 an effective and efficient regulator.

18 The Risk Task Group is responsible for  
19 efforts related to risk informing materials and waste  
20 arena activities, and we report directly to the Deputy  
21 Director of the Office of Nuclear Material Safety and  
22 Safeguards.

23 As a result of our workshop in April 2000,  
24 it was suggested that we consider case studies as a  
25 way to determine which activities in the materials and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 waste arenas would be both possible and beneficial to  
2 risk inform. The case studies were designed to cut  
3 across a spectrum of activities within the office.

4 We planned to do several things. We  
5 wanted to test the draft screening criteria that were  
6 developed to enable us to determine if a proposal was  
7 amenable to risk informing, to tease out any possible  
8 safety goals that were imbedded in the regulations or  
9 the staff actions, to determine the feasibility of  
10 developing broader safety goals, and to gain insights  
11 on risk-informing regulatory processes which include  
12 the identification of tools, data, methods and  
13 guidance that would be needed to support a risk-  
14 informed approach.

15 As the case studies were underway, we held  
16 public meetings for each case study area in order to  
17 get early stakeholder involvement into the process.  
18 At each of these public meetings, we stated we would  
19 hold a stakeholder meeting at the conclusion of all  
20 the case studies to discuss what we learned and to  
21 discuss our future direction. Today is that day.

22 Our meeting today has three primary  
23 objectives. We will summarize in an integrated  
24 fashion the results of the case studies as they  
25 applied to our case study action plan objectives. We

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 will make our presentation such that we will tell you  
2 our present plans for moving forward with risk  
3 information activities in the materials and waste  
4 arenas, and the third will be to solicit your comments  
5 and recommendations on what we have discussed here  
6 today.

7           Today's meeting will be somewhat different  
8 than our past meetings on the case studies. One of  
9 the differences which you might have already noticed  
10 is the use of posters to summarize the insights we  
11 gained during the case study process. Also, as we  
12 progress with the meeting, our agenda will be somewhat  
13 more fluid than in the past.

14           The morning session will be primarily  
15 devoted to the integration and lessons learned from  
16 the case study material, which we will cover in the  
17 first two hours of the meeting. This will include  
18 focusing on the final screening considerations,  
19 including its guidance and application, regulatory  
20 process improvements including tools, methods and  
21 data, and an introduction to the concept of safety  
22 goals and why we think they are important.

23           Later in the morning and in the afternoon,  
24 we will seek your input on these matters, particularly  
25 in regard to process improvement aspects and what we

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 should look at next, and your thoughts on developing  
2 safety goals that define what safety may mean in the  
3 materials and waste arenas.

4 At this time, we plan to synthesize all  
5 the individual case study reports and perhaps other  
6 risk-related information into one consolidated report  
7 and send it to the Commission sometime in January.

8 We had promised that we would put out our  
9 draft case study reports on the Website to allow for  
10 sufficient time to review before this meeting.  
11 However, due to the tragic events of September 11th,  
12 many things about how the NRC does business are in a  
13 state of change.

14 There is a renewed sense of caution about  
15 what information about our licensees and the products  
16 we regulate should be made public. Although the  
17 documents and references used for the case studies  
18 have been publicly available, we decided to err on the  
19 side of caution and not place the synthesized case  
20 studies on the NRC Website. The decision was reached  
21 in context with overall NRC policy in light of the  
22 September 11th tragedy. I apologize if this caused  
23 any undue problems.

24 I do think that we should be able to reach  
25 our meeting objectives today without the case study

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 reports. Furthermore, I hasten to point out that we  
2 will not directly discuss sabotage, security or  
3 safeguards issues at this meeting. However, I would  
4 like to note my personal view that risk assessment and  
5 management techniques and strategies can be especially  
6 useful in our work post-September 11th, in that risk  
7 and vulnerabilities can be identified and assessed so  
8 that we can marshal our resources to the most  
9 appropriate areas.

10 As before, I am grateful for Dr. Patricia  
11 Rathbun, who will be our Facilitator today and will  
12 coordinate our group discussion. In terms of our  
13 agenda, Dr. Margaret Federline, Deputy Director of our  
14 office, will provide an overview of the management  
15 philosophy on risk-informing NMSS regulatory  
16 activities. She will be followed by Ms. Marissa  
17 Bailey, who will present an overview of the case  
18 studies; Ms. Raeann Shane, who will go over the  
19 screening considerations in the proposed guidance and  
20 use; Dr. Dennis Damon and Dr. Robert Bari will make a  
21 presentation on our perspectives on safety goals; who  
22 will be then followed by Mr. James Smith, who will  
23 speak on process improvements. Finally, Mr. James  
24 Danna will tell you where we plan to go from here.

25 At the conclusion of the presentations,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 there will be time for a group discussion and feedback  
2 session, and this will be continued after lunch. I  
3 expect to conclude this meeting around 4:30 this  
4 afternoon. I would also like to point out that we  
5 will have subject matter experts from each of the four  
6 divisions within NMSS, as well as from Brookhaven  
7 National Laboratory, who will support us today, and I  
8 thank them for their continuing assistance.

9 Also as before, let me say that this  
10 meeting is open to everyone, including NRC staff,  
11 licensees, applicants, Federal, State, tribal and  
12 local government organizations, non-government  
13 organizations, public citizens groups, manufacturers,  
14 users, industry and trade association representatives,  
15 and members of the general public. Everyone is  
16 invited to provide any thoughtful insights or  
17 commentary on this case study as applied to our  
18 objectives.

19 Finally, we will be seeking your feedback  
20 on what you thought about this meeting. One way of  
21 doing so is a feedback form you can mail into us, or  
22 you can provide any comments directly to one of us  
23 making a presentation today.

24 Before we begin with the actual case study  
25 presentations, let me introduce Ms. Margaret

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Federline. As Deputy Director of the Office of  
2 Nuclear Material Safety and Safeguards of the U.S.  
3 Nuclear Regulatory Commission, Ms. Federline is  
4 responsible for regulatory programs to ensure that  
5 users of nuclear materials do so in a manner that  
6 protects public safety and the environment, safeguards  
7 special nuclear material and appropriately control the  
8 management and disposal of radioactive waste. Her  
9 broad experience has been recognized internationally,  
10 where she currently serves as the Chairman of the  
11 OECD, Nuclear Energy Agency, Radioactive Waste  
12 Management Committee.

13 Prior to assuming her current  
14 responsibilities in NMSS, she served in increasingly  
15 responsible Senior Executive Service positions,  
16 including Deputy Director of the Office of Nuclear  
17 Regulatory Research, Deputy Director of the Division  
18 of Waste Management, and Chief of the Performance  
19 Assessment and Hydrology Branch.

20 Ms. Federline also served as Senior Policy  
21 Advisor to Chairman Kenneth M. Carr, and Assistant to  
22 the Executive Director for Operations at the NRC.  
23 Before joining the Federal Government in 1979, she  
24 participated in life science research, including an  
25 experiment which flew on the MARS Viking Lander. In

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 addition, she developed and managed a commercial  
2 analytical chemistry and industrial hygiene  
3 laboratory. While serving at the National Institute of  
4 Standards and Technology, she led the development of  
5 a national system for accrediting laboratories. She  
6 joined the NRC in 1981, where she focused on  
7 development of occupational radiation protection  
8 standards.

9 She has been very supportive of our  
10 efforts to date, and I look forward to her continuing  
11 involvement and assistance.

12 DR. FEDERLINE: Thanks, Lawrence, I  
13 appreciate that introduction. I always say the only  
14 thing worse is having a boss who is really interested  
15 in what you are doing, and I have a life-long interest  
16 in risk assessment which will probably pick up in some  
17 of my remarks today.

18 We really appreciate you coming today.  
19 This is a very important meeting for us. We hope that  
20 you will participate actively in the dialogue. The  
21 staff that you see here today has put in a tremendous  
22 amount of effort, groundbreaking effort, I think, in  
23 the materials area, to pull together the case studies,  
24 and this is our opportunity to discuss them with you  
25 and get some feedback from you. So, I really

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 encourage you to participate in that dialogue.

2 As you are aware, this meeting is part of  
3 an ongoing process to develop methods for using risk  
4 information in NMSS. The objective of this effort is  
5 to improve the regulation of materials and waste,  
6 emphasizing a focus on safety.

7 The goal of NRC safety regulation is to  
8 prevent unintentional harm to the public, but as we  
9 have all seen with the tragic events that surrounded  
10 September 11th, it emphasizes that the public is also  
11 at risk from intentional harm.

12 It is the mission of the Agency as well as  
13 NMSS to protect the public from both kinds of harm,  
14 and in light of the current events the Commission has  
15 really taken immediate action both internally and with  
16 our licensees to protect the public from terrorist  
17 acts involving nuclear materials.

18 The NRC and its many regulated facilities  
19 have been placed in a higher state of alert and  
20 readiness, and the Chairman has directed the formation  
21 of a task force to re-examine all the assumptions  
22 underlying our safeguards and security regulations,  
23 and I am chairing that task force. I had hoped to  
24 spend the day with you today, but unfortunately I am  
25 going to be in and out as a result of some of those

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 responsibilities.

2 Now, one of the specific actions taken as  
3 a result of the terrorist acts was to remove much of  
4 the material, as Lawrence said, from the NRC Website.  
5 This was an extremely painful thing for us. The  
6 Agency has a history of being a very open agency,  
7 sharing all information, but we felt that it was a  
8 prudent measure and needed to be done to ensure that  
9 all the material on the Website had been reviewed for  
10 any items that could be beneficial to terrorists.

11 Now, this action, as Lawrence said,  
12 prevented us from posting some of the information for  
13 this meeting, and I regret any inconvenience that it  
14 caused you as participants in being able to prepare  
15 for this meeting, but you will see that my colleagues  
16 here have done an extra special effort to try and make  
17 sure that they discuss with you all the aspects of the  
18 case studies, to try and make up for some of the  
19 information that we couldn't put on the Web.

20 We are expediting our effort to review the  
21 materials that were taken off the Web, and we are  
22 trying to put back materials as rapidly as possible,  
23 and we are committed to putting back as many materials  
24 as possible onto the Website.

25 Now, risk information can have multiple

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 uses. Protection against the risks of deliberate harm  
2 shares many common elements with protection from  
3 accident risks. For example, the robustness of many  
4 containers for nuclear materials makes them difficult  
5 to damage, whether intentionally or by accident.

6 We expect that the information and risk  
7 insights that come out of this work will not only  
8 complement our safety mission, but will also help us  
9 in many of the activities that we are performing to  
10 make our regulations more effective against terrorist  
11 acts as well.

12 Now, as Lawrence explained, the purpose of  
13 the meeting is to continue the process of risk-  
14 informing appropriate areas of regulation within NMSS.  
15 Now, risk-informed for me means the use of risk  
16 information to gain insights, and to improve our  
17 regulatory process. And I see this as a win-win for  
18 everyone, all the stakeholders and the NRC staff to  
19 boot.

20 Our insights are going to be used to  
21 improve the focus of our regulatory efforts, and I am  
22 sure on the part of stakeholders there is a concern  
23 about whether we are going to throw everything out and  
24 start over again. That is certainly not the case.

25 We intend to use the benefits that we gain

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 from these risk insights to improve the focus of our  
2 programs. That means increasing our own effectiveness  
3 and efficiency internally by the information that we  
4 learn from these studies, as well as imposing more  
5 focused regulatory requirements, lessening burden in  
6 areas that are shown to have less significance to  
7 safety, and improving our focus to safety in other  
8 areas.

9 The results of this work may identify new  
10 vulnerabilities, or they can change the emphasis on  
11 ones that we already know about. It could also lead  
12 to more robust safety requirements. Such risk-  
13 informed reasoning augments traditional safety  
14 principles, it doesn't replace the things that we've  
15 relied on for so long to ensure the protection of  
16 public health and safety, ensuring that there are  
17 adequate margins in our regulation, using the best  
18 engineering standards, and emphasizing the use of  
19 defense in depth in our regulatory process.

20 Now, the Office of NMSS regulates many  
21 diverse areas. The nuclear facilities and devices  
22 involved have different risks and really different  
23 needs for protection. A number of issues arise in  
24 these areas. Risk information will provide varying  
25 insights in these different areas and, thus, the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       appropriateness of using risk information is expected  
2       to vary across NMSS.

3               I just want to emphasize that one size  
4       doesn't fit all, and we are not attempting to make one  
5       size fit all. For this reason, the Risk Task Group  
6       selected eight very widely different areas in which to  
7       conduct case studies in order to gain risk insights on  
8       methods for the use of risk information. During this  
9       meeting, the Task Group will report to you what has  
10      been learned in each of these eight case studies.

11              Now, the insights from these case studies  
12      have resulted in plans for future action, and those we  
13      want to get your insights and get your feedback on  
14      those plans for further action. Among the future  
15      actions could possibly be the development of guidance  
16      on risk methods and the application of these methods  
17      in various areas across NMSS.

18              The overall goal, as I emphasized before,  
19      is to realize the benefits in improving our efficiency  
20      and effectiveness and improving our focus on safety,  
21      and reducing regulation in areas that are less  
22      significant to safety.

23              Now, for the remainder of the morning, the  
24      Risk Task Group will summarize the case studies. This  
25      afternoon, there will be a discussion facilitated by

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Dr. Pat Rathbun to obtain feedback from you on these  
2 insights and on future plans, and I encourage you to  
3 participate actively in this process. This is your  
4 opportunity, including the NMSS staff that are in  
5 attendance today, to jump in and be part of the  
6 discussions and make sure that your feelings are  
7 known. In light of the current environment that we  
8 live in, we must learn how to be more effective and  
9 efficient in our mission.

10 Now I would like to turn it over to  
11 Marissa Bailey, of the NMSS Risk Task Group. Marissa  
12 is the Senior Project Manager for the case study  
13 project whose results will be presented today.

14 MS. BAILEY: Thank you, Margaret.

15 Good morning. My name is Marissa Bailey.  
16 I am the Senior Project Manager of the Risk Task  
17 Group. Over the last year, the Risk Task Group has  
18 been conducting case studies. These case studies are  
19 basically retrospective looks at a spectrum of  
20 activities in the materials and waste arenas. We  
21 started conducting these case studies so we could  
22 evaluate what has been done or what could be done in  
23 the materials and waste arenas with respect to the use  
24 of risk information, and also so that we could begin  
25 to establish a framework for using risk-informed

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 approaches in the materials and waste arenas.

2 The objectives of these case studies are  
3 to test the draft screening criteria and ultimately  
4 produce a final version, to determine the feasibility  
5 of safety goals and, if possible, to develop a first  
6 draft to gain insights on how the use of risk  
7 information has improved or could improve our  
8 regulatory processes, and to gain insights on the  
9 methods, data, guidance and tools needed to implement  
10 a risk-informed regulatory approach.

11 As Margaret mentioned, in our next  
12 presentations, we will be presenting to you what we  
13 have learned from the case studies. We would like to  
14 tell you where we are and where we are going with  
15 respect to those four objectives.

16 (Slide.)

17 I would like to begin the presentations by  
18 giving you an overview of the case studies. In my  
19 presentation, I will basically be giving you  
20 background information, and also summarizing some of  
21 the insights that we have gained from the case  
22 studies. The presentations that follow mine will be  
23 giving more detailed insights.

24 (Slide.)

25 In the last few years, NMSS has been in

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the process of developing an approach for using risk  
2 information in the nuclear materials and waste arenas.  
3 This basically is part of an overall effort within the  
4 NRC that stems from the Commission's 1995 PRA Policy  
5 Statement to supplement our traditional deterministic  
6 regulatory approach with a risk-informed regulatory  
7 approach.

8 Basically, we see risk information as  
9 simply a way for us to keep our focus on safety, to  
10 improve our regulatory decisionmaking process, to make  
11 more effective use of our resources, to reduce  
12 unnecessary regulatory burden, and also to help us  
13 identify and address shortcomings in our current  
14 regulatory system.

15 The framework for risk-informed  
16 regulations in the materials and waste arena is  
17 detailed in a March 1999 Commission paper which is  
18 known as SECY-99-100. This Commission paper  
19 introduced a systematic five-step process for moving  
20 toward risk-informed regulations, and those five steps  
21 basically are to identify the candidate regulatory  
22 applications that are amenable to expanded use of risk  
23 assessment information, to make a decision on how to  
24 modify the current regulatory approach so that it is  
25 more risk-informed, to change the current regulatory

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 approach, to implement that risk-informed approach,  
2 and to develop or adapt existing tools and techniques  
3 of risk analysis to the regulation of nuclear  
4 materials and waste.

5 I would like to point out that steps 2  
6 through 5 don't necessarily need to be taken in  
7 sequence. These steps could be interchanged or they  
8 could occur in parallel. I would also like to point  
9 out that at this point in time, we are basically in  
10 Step 1, although there are some areas in the materials  
11 and waste arenas that are further along in this five-  
12 step process but, in general, we are early in the  
13 process of identifying regulatory applications that  
14 are amenable to risk-informed regulation.

15 (Slide.)

16 In a June 1999 Staff Requirements  
17 Memorandum, or SRM, the Commission approved the  
18 proposed framework in SECY-99-100. In this SRM, the  
19 Commission also directed the staff to develop  
20 appropriate materials and waste safety goals analogous  
21 to reactor safety goals. In that SRM, the Commission  
22 also stated that these goals should guide the NRC  
23 staff and should define what "safety" means for the  
24 materials and waste program. The Commission also  
25 stated that in developing these goals, the staff

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 should include avoidance of property damage, consider  
2 whether critical groups can be defined for classes of  
3 material and use, and give due consideration to 10 CFR  
4 Part 20. So, SECY-99-100 and the associated SRM in  
5 the last year and a half have sort of been our guide  
6 as to what we've been doing in the Risk Task Group.

7 (Slide.)

8 To help us identify those candidate  
9 regulatory applications -- again, Step 1 of the five-  
10 step process -- we drafted screening criteria. Now,  
11 this screening criteria, once finalized, would be a  
12 decisionmaking tool. Basically, we are asking  
13 ourselves where in the regulation of materials and  
14 waste would risk insights provide a value. The intent  
15 of the screening criteria is to help us make those  
16 decisions in a consistent manner.

17 (Slide.)

18 The draft screening criteria basically  
19 consists of seven questions that we would ask to  
20 determine if an activity could be risk-informed. And  
21 I think one of your handouts include the screening  
22 criteria. The first four criteria basically ask  
23 whether a risk-informed approach would support the  
24 Agency's strategic goals of maintaining safety,  
25 improving efficiency and effectiveness, reducing

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 unnecessary regulatory burden, and enhancing public  
2 confidence.

3 A fifth criterion address the availability  
4 of quality data and models to support a risk-informed  
5 approach. A sixth criterion addresses the cost of  
6 implementing a risk-informed approach, and the seventh  
7 criterion addresses other precluding factors. Given  
8 that the activity passes the first six criteria, is  
9 there anything else that would or should prevent us  
10 from moving toward a risk-informed approach.

11 (Slide.)

12 A case study approach was adopted so that  
13 we could test the draft screening criteria, and also  
14 begin the process of examining the feasibility of  
15 safety goals. As I mentioned before, the case studies  
16 would be retrospective looks at the spectrum of  
17 activities in the materials and waste arenas and,  
18 individually and cumulatively, they should illustrate  
19 to us what has been done in the materials and waste  
20 arenas, were those activities risk-informed, and to  
21 what extent, and what lessons could be learned from  
22 them. Also, as I mentioned before, the objective of  
23 the case studies is to test the draft screening  
24 criteria and produce a final version, examine the  
25 feasibility of safety goals, and develop a first

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 draft, and also gain insights on process improvements  
2 and what tools we would need to implement the risk-  
3 informed approach.

4 I would like to point out that the intent  
5 of the case studies is not to reopen or reassess  
6 previous decisions made by the staff and the  
7 Commission.

8 (Slide.)

9 How we have conducted the case studies is  
10 outlined in a case study plan which we published in  
11 October 2000, and that case study plan has been made  
12 available in our previous stakeholder meetings.

13 (Slide.)

14 The case studies basically involve  
15 answering three sets of questions that are designed to  
16 meet the four case study objectives. These questions  
17 are screening criteria/risk analysis questions, safety  
18 goal analysis questions, and then questions that would  
19 be asked once we've developed draft safety goals.

20 (Slide.)

21 The case studies that were conducted are  
22 in the following areas: gas chromatographs, static  
23 eliminators, fixed gauges, uranium recovery, site  
24 decommissioning of the Trojan Nuclear Plant,  
25 transportation of the Trojan Reactor Vessel, dry-cask

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 storage of TMI-2 fuel debris at the DOE/INEEL  
2 facility, and specifically focusing on the seismic  
3 exemption for that licensing process, and the Paducah  
4 Gaseous Diffusion Plant seismic upgrades.

5 These activities were chosen because they  
6 had elements of risk-informed decisionmaking, or they  
7 were perceived to be activities that could benefit  
8 from risk-informed decisionmaking. And I hope that  
9 during our poster session earlier this morning, you  
10 were able to discuss these case studies with our Risk  
11 Task Group staff and also with our colleagues from  
12 Brookhaven National Laboratory.

13 What I'd like to do at this point is just  
14 summarize for you some of the main insights that we  
15 have gained from those case studies, and the  
16 presentations that follow mine will be going into more  
17 detail with those insights.

18 (Slide.)

19 With regard to the screening criteria, we  
20 basically found that they encompassed relevant  
21 considerations, and that they should be taken as  
22 considerations rather than as criteria, so at this  
23 point I am going to be referring now to the screening  
24 criteria as screening considerations instead. And  
25 this is just to basically reflect the fact that those

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 set of seven questions should be taken as a whole, and  
2 that it is one tool for decisionmaking.

3 We also found that the screening  
4 considerations is a useful decisionmaking tool, and  
5 the we are at a point now where we are ready to  
6 finalize them. However, we did find that the  
7 application of these considerations could be  
8 subjective and that guidance is needed.

9 (Slide.)

10 With regard to safety goals, our case  
11 studies indicated that the development of safety goals  
12 is feasible for the materials and waste arenas. We  
13 also found that a multi-tiered structure similar to  
14 the safety goal structure for power reactors would be  
15 one possible approach and, if we did take that  
16 approach, we would have to develop subsidiary  
17 objections for each program area within NMSS. There  
18 were also examples in the case studies that showed  
19 that decisionmaking could be facilitated if a clear  
20 set of safety goals existed.

21 (Slide.)

22 With respect to the value of using risk  
23 information or process improvements that could be made  
24 with risk information, we basically found that in  
25 those case studies the application of risk information

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 helped us to make decisions that were consistent with  
2 the Agency's current strategic goals. We also learned  
3 that the use of risk information could be useful in  
4 helping us identify shortcomings in our regulations or  
5 regulatory processes. And as far as tools, methods,  
6 data, guidance and information, we found that that's  
7 a mixed bag within NMSS, that in some areas tools and  
8 methods and guidance are developed to support a risk-  
9 informed approach. In some areas, there are tools  
10 available, but more would need to be developed, and  
11 that in some areas we need to develop some, that there  
12 are none available.

13 That basically concludes my presentation.  
14 As I've said before, the next presentations will give  
15 you more detailed insights from the case studies,  
16 beginning with Raeann Shane, who will be talking to  
17 you about the screening considerations. Thank you.

18 MS. SHANE: Thank you, Marissa. Good  
19 morning, everyone. My name is Raeann Shane, and I am  
20 a Health Physicist with the Risk Task Group, and I  
21 will be speaking this morning on the screening  
22 criteria.

23 (Slide.)

24 As Marissa just explained, we have been  
25 working on case studies in the materials and waste

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 arenas for the last year. One of the objectives of  
2 the case studies was to test a set of draft screening  
3 criteria, and to develop a set of final screening  
4 criteria with the help of public input.

5 (Slide.)

6 The screening criteria, taken as a group,  
7 provided a tool to help the NMSS staff decide whether  
8 risk-informing, particularly in the regulatory arena,  
9 would be possible and beneficial. In order to test  
10 the screening criteria, the staff applied them to the  
11 subject matter of the case study as if the decision to  
12 risk inform the subject were being made at that time.  
13 Through this process, the staff was able to determine  
14 the effectiveness of the draft criteria, and also to  
15 determine where additional guidance or changes might  
16 be necessary to the screening criteria.

17 (Slide.)

18 From comments received during the past  
19 public meetings and from insights gained during the  
20 completion of the eight case studies, it was decided  
21 that the term "screening criteria" should be replaced  
22 with "screening considerations", as Marissa mentioned  
23 earlier. This term reflects the idea that these seven  
24 factors are one tool in the management decision  
25 process to risk inform a particular regulatory

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 activity. The revised screening considerations are in  
2 one of your handouts. And when we were revising the  
3 screening considerations to try to achieve a final  
4 set, the staff of RTG believed that most of the  
5 changes needed were minor wording changes.

6 The most notable changes are that some of  
7 the considerations, such as No. 6, previously had  
8 parenthetical guidance statements which are now being  
9 incorporated into the screening considerations  
10 guidance document. This will enable us to present one  
11 consolidated guidance document which will be designed  
12 for the staff's use when applying the considerations  
13 to their work.

14 The need for guidance became evident  
15 during the process of completing the case studies.  
16 Many of the staff and stakeholders felt that the  
17 screening criteria were subjective in nature and could  
18 be used to produce a pre-determined outcome. The  
19 objective of the guidance will be to more fully  
20 explain what the staff should be thinking about when  
21 answering the seven questions, and we are open to your  
22 input today on additional aspects for guidance. We  
23 plan to have the guidance document issued concurrently  
24 with our final report on the case studies.

25 (Slide.)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 I will now go over the revised screening  
2 considerations and what we were thinking about for  
3 rough ideas for guidance.

4 No. 1. Could a risk-informed regulatory  
5 approach help resolve a question with respect to  
6 maintaining or improving the activity's safety?

7 And what the staff should be thinking  
8 about when applying considerations is does the  
9 activity's safety level need improvement, or is the  
10 activity safe enough, but other aspects of the  
11 regulatory framework could use improvement while still  
12 maintaining safety, or would risk information be  
13 useful in assessing a new activity's safety level?

14 (Slide.)

15 The second screening consideration is  
16 could a risk-informed regulatory approach improve the  
17 effectiveness or efficiency of the NRC regulatory  
18 process?

19 And what the staff should be thinking  
20 about in this case is are there aspects of the  
21 regulatory framework which could be streamlined  
22 through the use of risk information, or could the use  
23 of risk information produce more consistent decisions  
24 among NRC staff?

25 (Slide.)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           The third consideration is could a risk-  
2 informed regulatory approach reduce unnecessary  
3 regulatory burden for the applicant or licensee?

4           And for the staff guidance, we have:  
5 Could risk information be used to change regulations  
6 or policy so that the regulatory burden is more  
7 consistent with hazard, or could risk information be  
8 used to change NRC licensing or inspection policies to  
9 focus the most effort on those areas that have the  
10 biggest safety impact, while still maintaining overall  
11 safety?

12                   (Slide.)

13           No. 4, would a risk-informed approach help  
14 to effectively communicate a regulatory decision?

15           And the staff guidance is, could risk  
16 information be used to provide a better understanding  
17 of the basis for a decision, or would risk information  
18 make staff decisions more clear and defensible, or  
19 provide greater transparency to our process?

20                   (Slide.)

21           No. 5, do information such as data and/or  
22 analytical models exist that are of sufficient quality  
23 or could they be reasonably developed to support risk-  
24 informing a regulatory activity?

25           And the staff should be thinking about, in

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 this case, identifying what risk studies have been  
2 done and examining them to determine do they cover the  
3 relevant uses for the activity, the isotopes involved,  
4 the quantities of those isotopes, et cetera; are the  
5 studies complete, and are they up-to-date, do they  
6 reflect our current regulatory environment? And if  
7 computer codes are necessary, are those codes  
8 available, are they codes which could be modified, or  
9 would we have to start from square one?

10 (Slide.)

11 The sixth criteria, can startup and  
12 implementation of a risk-informed approach be realized  
13 at a reasonable cost to the NRC, applicant or  
14 licensee, and/or the public, and provide a net benefit?

15 This is the consideration which I  
16 mentioned earlier that had the parenthetical  
17 reference, and the referenced introduced the concept  
18 of net benefit. The net benefit could be improvement  
19 to public health and safety, improve protection of the  
20 environment, improve communication or better  
21 regulatory efficiency at the same safety level, which  
22 would result in a cost-savings to the public.

23 (Slide.)

24 And, finally, No. 7, do other factors  
25 exist which would limit the utility of implementing a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 risk-informed approach?

2 In this case, the staff should consider  
3 other precluding factors, which might be things such  
4 as legislative or judicial decisions which would limit  
5 the implementation of a risk-informed approach, long-  
6 standing Agency policy issues, or other social  
7 considerations.

8 (Slide.)

9 So, these are the considerations in  
10 revised form. We believe the considerations are a  
11 useful tool in the decisionmaking process, and later  
12 on today Jim Danna will be talking about where the  
13 screening considerations will be used. We also  
14 believe the screening considerations cover the  
15 relevant areas that should be considered when  
16 contemplating a regulatory change. And, as I stated  
17 earlier, we are seeking input into the guidance today,  
18 and we hope to have the guidance document finalized  
19 and issued with the final case study report.

20 That concludes my remarks, and I would  
21 like to introduce Dr. Dennis Damon, who will be giving  
22 you the safety goal presentation.

23 DR. DAMON: Thank you, Raeann. As Marissa  
24 Bailey discussed earlier, the case studies  
25 investigated several things. One of them were the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 screening criteria that Raeann just went over.  
2 Another topic is safety goals, which I am going to  
3 address now.

4 The screening criteria tell you whether or  
5 not you should risk-inform an area -- in other words,  
6 should you do risk analysis to develop risk  
7 information. Safety goals address the question, what  
8 do you do with that risk information after you've  
9 gotten it.

10 What I'm going to do is just provide a few  
11 introductory remarks and then turn it over to Dr.  
12 Robert Bari, from Brookhaven National Lab. He and his  
13 colleagues at Brookhaven, including Vinod Mubayi, have  
14 been working on safety goals for many years, and they  
15 are supporting us in this effort, and they have  
16 brought a number of insights into safety goals drawn  
17 from these case studies, but to set the perspective on  
18 this, I'm going to try to make four points.

19 (Slide.)

20 The first point is one I've already  
21 mentioned, which is that the functions of the case  
22 studies was to evaluate whether safety goals made  
23 sense, was this something that would be useful in the  
24 context of NMSS as opposed to reactors? As Director  
25 Federline mentioned, NMSS covers a wide variety of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 diverse things. It is not clear whether safety goals  
2 are feasible because of the magnitude and the scope of  
3 what NMSS does, or they may not be necessary because  
4 they know enough about them given where they are at.  
5 So, the question was, are safety goals feasible and  
6 useful in NMSS, and the case studies were looked at to  
7 answer that question.

8 The conclusion was that in several cases  
9 it was noted that quantitative measures of "what is  
10 safe enough" would have been useful.

11 (Slide.)

12 The second point I'm going to address is  
13 what is a safety goal because it is a subtle and  
14 complex concept, and Dr. Bari will get into some of  
15 the issues that come up.

16 The second point of what are safety goals,  
17 the simplest answer is "how safe is safe enough"?  
18 That is a subtle concept. It really is intended in  
19 this context -- there may be other contexts where  
20 these terms are used -- but in this context, what we  
21 are meaning by a safety goal is a level of risk that  
22 is very, very low. It is so low that when you've made  
23 something that safe and all you know is that it is  
24 that safe, then it is clear to you that is safe  
25 enough, as opposed to a case where you're trying --

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 you don't believe it's at the absolute level of safety  
2 that would be clearly safe enough, and you can't make  
3 it any safer, you are trying but you are not getting  
4 there, but you've reached a level that perhaps is as  
5 good as you can do. That is not what a safety goal --  
6 a safety goal is not as good as you can do, a safety  
7 goal does not pay any attention to how good you can  
8 do, it is only the absolute level of safety -- is that  
9 safe enough?

10           There can be more than one type of safety  
11 goal. The reactor safety goals -- one reactor safety  
12 goal addresses risk to individuals. Another one  
13 addresses risk to society. And the difference there  
14 is, a risk to an individual means what is your chance  
15 of being harmed? Risk to society adds that up over  
16 the whole population, so it is a total picture of the  
17 risk from some thing, a facility or whatever.

18           The bottom line up there is safety goals  
19 are aspirations, not requirements. That conceptual  
20 mistake is often made, that's one of the reasons I  
21 included this in my introductory remarks. You have  
22 got to keep in mind that a safety goal is something  
23 that you would like to achieve, but you can't mandate  
24 it because it does not consider whether it is  
25 physically possible to do it. It doesn't consider

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 whether it is practicable to do, or reasonable to  
2 require it. It only considers it from an absolute  
3 point of view.

4 (Slide.)

5 Top level safety. Here is another concept  
6 about safety goals. They could be qualitative or  
7 quantitative. It is a simple concept. Those of you  
8 who are familiar with reactor safety goals will know  
9 what I'm talking about.

10 An example of a qualitative safety goal  
11 statement is given on this slide. Risks from nuclear  
12 accidents to individual members of the public near a  
13 facility should be an insignificant addition to other  
14 risks. It is not a quantifiable thing, but it is a  
15 concept, a qualitative concept of what level of safety  
16 is appropriate, namely, should be an insignificant  
17 level.

18 (Slide.)

19 A quantitative of a safety goal would be  
20 the frequency of accidental radiation exposures to the  
21 general public exceeding 100 mrem from a facility  
22 should be less than x, where x is some specific  
23 number. So, the idea of a quantitative safety goal is  
24 something very specific or quantitative to which the  
25 results from a risk analysis could be compared. A

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 quantitative risk analysis calculates a number, and  
2 this is a number to which it can be compared. So,  
3 that's the difference between qualitative and  
4 quantitative, and that gives you a feel for what we  
5 mean by safety goals.

6 (Slide.)

7 A third point I wanted to make is that the  
8 topic of this meeting and the goal of the effort the  
9 Risk Task Group has embarked on is not just safety  
10 goals, it is risk-informed regulation which is a much  
11 broader topic. Safety goals is one specific narrow  
12 area of that broader topic. Risk-informed regulation  
13 involves all beneficial uses of risk information, like  
14 evaluating the relative quantitative risk impact of  
15 various actions. You will learn from that something  
16 about which things are more important to the actual  
17 bottom line risk. What a safety goal is, remember, is  
18 simply a level of risk that when you have reached that  
19 you know you are safe enough, and that's just that  
20 one. It just addresses that one specific issue.

21 (Slide.)

22 The fourth point I wanted to make is why  
23 have safety goals. And you can sense from the  
24 screening criteria why you would want to have safety  
25 goals. That's what the screening criteria kind of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 lead you toward, is the idea of what are you going to  
2 use risk information for? Safety goals are involved  
3 in that same reasoning process, but they are just one  
4 way you might reason using risk information. On the  
5 reactor side and in other countries, safety goals have  
6 proven useful in reducing burden and improving  
7 effectiveness, regulatory effectiveness. It allows  
8 you to identify when you've gone far enough and,  
9 therefore, not waste staff time or impose excessive  
10 burden.

11 It also tells you --the second bullet up  
12 there says what risk metrics should you calculate?  
13 People tend to focus on safety goals and say you are  
14 really just focusing on what level of safety is safe  
15 enough. Actually, in a way, more importantly, you  
16 have to identify first what risks are you going to  
17 consider. There are more than one type of risk.  
18 There is risk to the public. There is risk to  
19 workers. There are different type forms of risk.  
20 There is risk of fatality and injury. There is  
21 chronic exposure. There is accident exposure. There  
22 is even terrorist exposure. There are different kinds  
23 of risks. It is very useful to risk-informing if you  
24 identify what all these kinds of risks are so that you  
25 are sure that your staff is considering all the things

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 that they should be considering.

2 After you have identified the areas they  
3 should consider, then the question comes up, what  
4 level of risk in that area is low enough? So, there's  
5 really two steps to safety goals -- identifying the  
6 risk metrics or the considerations that you are going  
7 to factor into your "how safe is safe enough", and  
8 then what level of them is safe enough.

9 So that concludes my presentation. I'm  
10 going to introduce now Dr. Robert Bari, from  
11 Brookhaven National Lab. Dr. Bari and his colleagues  
12 there have worked for many, many years on safety goals  
13 and use of risk information, and here is Dr. Bari.

14 DR. BARI: Thanks, Dennis. My name is  
15 Robert Bari. I work at Brookhaven Laboratory. Good  
16 morning.

17 (Slide.)

18 Just to recapitulate what Dennis just told  
19 you, the fundamental purpose of safety goals is to  
20 articulate the Agency's safety philosophy.  
21 Secondly, it is really there to establish a level  
22 of insignificant risk, risks beyond which one would  
23 not really have to take further actions or consider  
24 improvements in a facility or process. This sometimes  
25 is colloquially referred to as "how safe is safe

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 enough". Importantly, the safety goals are very  
2 helpful in facilitating risk management. If you have  
3 safety goals, it provides aiming points to understand  
4 which activities require more attention, which require  
5 less attention. It's a very good approach to  
6 understanding how to manage a facility. And as Dennis  
7 emphasized and it cannot be overscored here, these are  
8 not requirements. There are requirements in the  
9 regulations, but these are aspirations of levels to be  
10 strove for but likely not to be met in general.

11 (Slide.)

12 Just in the way of background, work on  
13 safety goals started in the nuclear area in the U.K.  
14 back in the late '60s. Reginald Farmer developed what  
15 was called the "limit line", where he looked at  
16 probabilities and consequences, and developed a sense  
17 of what type of risks were acceptable, what type of  
18 risks would be unacceptable.

19 In the early 1980s, safety goals came to  
20 NRC, at least for the power reactors -- this was  
21 following the Three Mile Island accident. As some of  
22 you might recall, over about a six-year period, safety  
23 goals were put forth on a trial basis draft form,  
24 discussed with many stakeholders. Excellent input was  
25 obtained. And, finally, in 1986, safety goals were

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 approved by the Agency and stand today, and are, in  
2 fact, being used by the Commission on a routine basis.

3 There have also been parallel efforts in  
4 other countries on the safety goal efforts. For  
5 example, in some countries, safety goals are actually  
6 codified into law, other countries have not adopted  
7 safety goals, others practice and use them more  
8 informally.

9 The international agencies, as well, have  
10 developed safety philosophies and safety criteria, in  
11 particular the IAEA and the NEA have, after Chernobyl,  
12 gone forward and taken another hard look at what  
13 safety really means, particularly for our facilities.

14 In the early '90s, or leading up to the  
15 '90s, the Department of Energy considered draft safety  
16 goals and had actually put them forth for some  
17 comment, but did not finally approve them when the  
18 Administration changed in our government.

19 And, finally, and probably very important  
20 to this effort, is that following events in Japan over  
21 the last half a dozen years or so, the Ministry has  
22 tasked the nuclear agencies in Japan to develop safety  
23 goals, so this is a fresh look at safety goals across-  
24 the-board in Japan, not only for power reactors but  
25 for all types of facilities that come under regulation

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 in Japan -- nuclear facilities. So, this effort, as  
2 it moves forward here in the U.S., should stay in  
3 touch with what is being done by our Japanese  
4 colleagues.

5 (Slide.)

6 Just to also recapitulate some of the  
7 things Marissa said, in the materials use and waste  
8 areas, the guiding document here is really SECY-99-  
9 100, a framework for risk-informing this area and, in  
10 particular, in this document, the thought is to  
11 propose developing metrics and goals following the  
12 general structure of reactor safety goals as they  
13 exist and have been approved back in '86. Also,  
14 importantly, to recognize that it is not only the  
15 public at risk, but the workers at risk. The safety  
16 goals that were approved in 1986 were silent on worker  
17 risks.

18 Also, rather unique to this area, also  
19 consider, in addition to accidents, normal operations  
20 at the various facilities that come under the Office  
21 of NMSS. Further, to look at the roles of other  
22 agencies and organizations, notably the Environmental  
23 Protection Agency, OSHA, and also Agreement States,  
24 among others; to take a look at what are the actual  
25 capabilities of licensees to do risk assessments which

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 would be needed to compare with safety goals; and,  
2 very importantly, a part of why we are here, is to  
3 seek broad stakeholder input as the safety goals are  
4 being developed.

5 As Marissa mentioned, the Commission  
6 concurred in a Staff Requirements Memo in the middle  
7 of 1999, on the basic approach, with certain caveats  
8 and additional guidance as outlined in Marissa's Vu-  
9 graph.

10 Now, as we move forward in our  
11 consideration of safety goals, there are some specific  
12 issues that need to be considered in framing safety  
13 goals. Importantly, should they be focused on  
14 individual risk, and perhaps also risk to society?  
15 Dennis had mentioned that a few minutes ago. In this  
16 area, in the materials use and waste area, you really  
17 run the gamut from activities that more or less impose  
18 involuntary risk, such as operating large facilities  
19 for some national purpose or some commercial purpose  
20 to other types of activities that exemplified in some  
21 of the posters outside, where there is a gradation of  
22 voluntary risk that comes into play, notably with  
23 workers and perhaps co-located workers. And, in fact,  
24 the whole concept of looking at worker risk needs  
25 examination as SECY-99-100 underscored. This, again,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 was an area that the earlier safety goal was silent  
2 on.

3 Some of the risk in these facilities, as  
4 our case studies have shown, not only involve the  
5 radiological hazard, but also non-radiological hazard  
6 -- for example, chemical hazards show up in various  
7 studies, particularly the ones in material use and  
8 production area.

9 Another important and different aspect of  
10 this area is that it is not only the operational phase  
11 of the facility or process that is of interest in  
12 regulation, but it is also longer-term risks, long  
13 after the facilities or processes have ceased that one  
14 needs to address.

15 So, in summary, the need here is to really  
16 recognize that these areas are qualitatively different  
17 from the issues that come from the reactor area. That  
18 is not to say that one should not take lessons learned  
19 and guidance from the reactor area, but one needs to  
20 fully recognize that there are many different issues  
21 that come up here in the non-reactor areas.

22 (Slide.)

23 So, in our case studies, we tried to glean  
24 implied safety goals or criteria that were perhaps  
25 used by the staff in some informal way -- we obviously

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 don't have any hard and fast safety goals at present.

2 (Slide.)

3 In the transportation risk study that was  
4 done, an accident probability of  $10^{-6}$  was judged to  
5 be, formerly in a de facto way by NRC, to be  
6 acceptable for vessel shipment. This is the Trojan  
7 Vessel shipment case.

8 In the case of site decommissioning and  
9 the long-term license termination rule and long-term  
10 release of a site, the unrestricted release of a site  
11 was pinned to the annual dose that would be received,  
12 residual dose, from that facility, and this was into  
13 a small fraction of the annual public dose limit of  
14 100 mrem per year.

15 In the uranium recovery, we found a more  
16 qualitative statement in the generic environmental  
17 impact statement that one should prevent significant  
18 adverse impacts of health and on the environment.

19 For the gaseous diffusion plant study that  
20 we did, health risks in particular, injuries to the  
21 public was determined to be sufficiently small to  
22 allow continued operation of the facility while the  
23 seismic upgrades were being made, as outlined on the  
24 poster that you saw outside.

25 (Slide.)

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Other case studies on this Vu-graph, the  
2 one on gas chromatographs and fixed gauges, where a  
3 sense of safety goals also was given in various part  
4 of the Code of Federal Regulations. And for static  
5 eliminators, it was put forth that there should be  
6 zero release from sealed sources.

7 In the case of storage -- this is the  
8 DOE/INEEL exemption -- 10 CFR 72, in its statements of  
9 consideration, recognized that the dry cask risk is  
10 less than nuclear power plant risk.

11 (Slide.)

12 In this Vu-graph, we consider where safety  
13 goals might have helped. In the three studies where  
14 risks were dealt with in a very up-front way -- for  
15 example, certification of a gaseous diffusion plant --  
16 the Trojan Reactor Vessel shipment exemption and,  
17 finally, the TMI-2 fuel debris storage activity at  
18 DOE/INEEL.

19 (Slide.)

20 Where they might help is, for example, the  
21 area of site decommissioning. It might be helpful  
22 particularly if one is looking at a facility where it  
23 is not clear whether to go for unrestricted release of  
24 the facility over the long-term, or restricted  
25 release. One might take an approach using a more

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 realistic assessment of the long-term scenarios.  
2 Right now, we look at a resident farmer scenario and  
3 going into the future 1,000 years, is that a realistic  
4 thing to do.

5 In the uranium recovery area, safety goals  
6 might be helpful in remediation alternatives with mill  
7 tailings, also might provide some helpful guidance in  
8 looking at weighing the non-radiological risks that  
9 some of these facilities pose.

10 In the transportation area, getting a  
11 better handle on worker and public risk connected with  
12 those activities. Dry cask storage, basically, to  
13 have a risk perspective would be very helpful. There  
14 are activities underway now within the Agency in that  
15 area.

16 And in the more broad area of byproduct  
17 materials, a consistent basis for licensing would be  
18 helpful to have here.

19 (Slide.)

20 The existing safety goal structure for  
21 power plants that was singled out in SECY-99-100 where  
22 it was recommended that one touch base with that or  
23 use that as a starting point for consideration, that  
24 approach is what is sometimes referred to as a three-  
25 tiered structure for safety goals. At the highest

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 level, one has a qualitative statement of the goals,  
2 and then a more quantitative one at a secondary level,  
3 and at the third level, which are objectives and not  
4 really hard and fast goals, one has what are called  
5 subsidiary objectives, and that is really where the  
6 rubber meets the road in risk management. Those have  
7 proven to be, in the case of power plants, the  
8 parameters that are most useful and most actively used  
9 in trying to determine the level of safety of a  
10 facility.

11 So, in the qualitative level, the items to  
12 consider are, again, the risks to the individual, both  
13 public and worker. Should they be considered a risk  
14 to society? Should one frame safety goal qualitative  
15 statements in that regard? And then, as also  
16 mentioned in the Staff Requirements Memo, the  
17 environmental and property damage risks, how should  
18 those be brought to the fore here.

19 At the quantitative level of objectives,  
20 there are items to consider as well. These are health  
21 objectives that would be spelled out in a very  
22 quantitative way and would give likelihood of health  
23 effects and, similarly, and what is not present in the  
24 current approved safety goals, is quantitative  
25 environmental objectives worthy of consideration.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           In the area of subsidiary objectives, we  
2           have a situation for facilities and processes in the  
3           materials use and waste areas where it is not only  
4           accidents -- what I call here, episodic type events --  
5           but also chronic exposure to a waste facility over the  
6           long-term. You are not having an accident or an  
7           event, there is a residual dose. And the question is,  
8           how does one recognize the risks there? How would one  
9           set safety goals which would recognize that?

10                   (Slide.)

11           This Vu-graph puts this together in terms  
12           of a matrix for the three tiers. The left-hand side  
13           is what we currently have for reactor operations. On  
14           the qualitative level, we have risk to individuals and  
15           societal risks. And if we move over to the right, the  
16           analogs or the counterparts might be similar things --  
17           risk to the individual and society, including public  
18           and workers as a possibility, and also environmental  
19           and property damage risk.

20           At the second level, we have a prompt  
21           fatality risk and a long-term cancer fatality risk.  
22           And, similarly, in the materials use and waste areas,  
23           we may consider again the quantitative health  
24           objectives which might have analogs to those, and also  
25           the development of quantitative environmental

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 objective.

2 At the third tier, the subsidiary  
3 objectives are core damage frequency -- that people in  
4 that business are all too familiar with -- and, also,  
5 a large early-release frequency. In the materials use  
6 and waste area, as I mentioned, there is a possibility  
7 of looking at chronic and episodic risks. In the  
8 chronic area, one might consider a subsidiary  
9 objective in terms of a dose rate. Dose rates tend to  
10 be very prominent in this area. We tend to see them in  
11 some of the criteria that are put forth. So, here one  
12 might consider a dose, let's say, in the millirem per  
13 year area, maybe ranging -- there might even be a  
14 range to consider somewhere between a single digit and  
15 a double-digit number in the millirem per year value.

16 (Slide.)

17 Episodic, what I've done here is tried to  
18 put together a sense of what the parameters might be  
19 for the various areas that are under consideration  
20 here. On the left-hand side -- and I'm not going to  
21 go through every one of these -- is the use or  
22 facility ranging from uranium milling, high level  
23 waste, spent fuel, and on the bottom I put the reactor  
24 operation area. And on the right-hand side, it would  
25 be the subsidiary objective parameter that might be

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 considered. So, clearly, for reactor operation, core  
2 damage and large early-release. But for, let's say,  
3 uranium milling, we might want to consider the  
4 likelihood of yellow cake release or chemical release.  
5 Pick another one, fuel fabrication could be a large  
6 radiological release, chemical releases again come in,  
7 and criticality, likelihood of criticality. Mill  
8 tailings, the likelihood of a release from an  
9 impoundment area.

10 So, these are some of the things, again,  
11 put up in the spirit of a strawman for consideration.  
12 We'd like to get your input on some of this.

13 (Slide.)

14 So, the next steps for us in the safety  
15 goal area is, first and foremost, to get your input on  
16 the value and need for safety goals in this area. We  
17 will be obtaining further insights from the case  
18 studies and other risk information, as we consolidate  
19 that and look forward to the second phase of this  
20 program, and part of that will be considering the  
21 development of draft safety goals.

22 Well, that concludes my talk. Thank you  
23 for your attention, and now I'm going to turn it over  
24 to Jim Smith.

25 MR. SMITH: Actually, before we start,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 let's go ahead and take a 15-minute break.

2 (Whereupon, a short recess was taken.)

3 MR. SMITH: My name is James Smith. I  
4 work with the Risk Task Group. I'm a Health Physicist  
5 here at the NRC. I've been with the Task Group for  
6 about two years now, so I may be the longest surviving  
7 one here.

8 (Slide.)

9 I was asked to speak about process  
10 improvements, things that we've identified during the  
11 case studies where we need to have some work done in  
12 order to realize the benefits of risk-informed  
13 regulation.

14 One of the things that we really need to  
15 do is to train our staff to realize that a risk-  
16 informed approach works, also to realize that there is  
17 going to be a consistent process to doing this. We've  
18 had consistent processes in the past. We give our  
19 staff guidance on just about everything they do, so  
20 something that will surely come to pass is that we  
21 will have to inform our staff, as was mentioned  
22 earlier, in what is an acceptable level of risk, and  
23 what levels does the Agency endorse as far as safety  
24 goals when, and if, that comes about.

25 The other thing that we need to let our

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 staff know is that risk-informed approach will be the  
2 preferred option. The Commission has said that in the  
3 past, but we need to let them know that if you are  
4 looking at different options, you need to realize that  
5 a risk-informed approach is the best option, or at  
6 least the preferred option.

7 (Slide.)

8 As far as screening  
9 criteria/considerations, one of the ways that we can  
10 teach our staff is to introduce this as a common  
11 guidance document, such as how to deal with rulemaking  
12 issues, how to deal with licensing particular  
13 licensees where an increase or a decrease in risk  
14 might be associated with a certain special  
15 authorization. Also, our inspectors, we are in the  
16 process now of revising our inspector guidance to  
17 focus on areas where there is the greatest amount of  
18 risk, not necessarily compliance inspections but more  
19 to focus on areas that get you the biggest bang for  
20 your buck.

21 (Slide.)

22 We still have a problem. In order to tell  
23 our staff what is the accepted level of risk, or at  
24 least where they should shoot for, we don't have one  
25 of those yet, so it's going to be a learning process

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 as we go along.

2 One of the issues that NRR did not have to  
3 deal with, as Bob mentioned earlier, is we have both  
4 long-term effects such as latent cancers that are  
5 developed, and we also have in some cases the  
6 opportunity to have what we call "deterministic  
7 effects", such as injury, permanent injury, perhaps  
8 death.

9 We also have the added safety goal option  
10 of considering property loss, and also public  
11 perception. Sometimes there are risks that may result  
12 in someone being injured, but there often are risks  
13 associated with just loss of control of material, and  
14 we lose public confidence in our ability to regulate  
15 this material that may not really result in a health  
16 risk to anyone or any sort of property damage, but we  
17 need to take into account the tolerable level of risk.

18 Also, one of the things that we really  
19 need to recognize as an Agency and work towards  
20 teaching our staff is zero is not always possible in  
21 the real world. And what I mean by that is our  
22 strategic goals are generally set, as well as our  
23 regulations, where zero noncompliance is acceptable.  
24 In reality, there is always going to be a certain  
25 possibility that your regulations might fail, that

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 some event that you don't want to happen will occur.

2 (Slide.)

3 We've looked at a number of models that we  
4 have out there right now. One that I'm most familiar  
5 with is NUREG 6642, which is a byproduct materials  
6 study. There is another document out right now, NUREG  
7 1717, that looks at a number of the types of materials  
8 that we have which we call "exempt", which, for those  
9 of you who don't know, those are generally the lowest  
10 level of control and generally no one who has one of  
11 these devices has to have any safety considerations.  
12 They just pick it up just like you would buying a  
13 computer. There are no instructions as to how to use  
14 it safely. Well, 1717 looked at those to see, well,  
15 what is the true risk associated with the distribution  
16 of these products.

17 (Slide.)

18 We also have ISA, the D&D codes. These  
19 are all models that we use. It helps to get a  
20 consistent approach to answering questions. We may  
21 not always be accurate, but at least we will be  
22 consistent.

23 We all have a problem in our regulations  
24 in the human factor. For the most part, if you could  
25 keep people away from material, then people don't get

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 exposed. Material doesn't get lost. But, generally,  
2 our licensees have to handle the material directly.  
3 There is an opportunity for someone to not follow  
4 procedure, or some other administrative detail, that  
5 may result in someone being exposed or material being  
6 lost.

7 One of the things that we have a problem  
8 with is people. It's awfully hard to predict what  
9 they are going to do in the future. They are just not  
10 very reliable sometimes. You can't always consider  
11 that a person is always going to push the right  
12 button.

13 (Slide.)

14 We have a number of options that we could  
15 do to address this weakness. We could start out by  
16 using NRR data and models for consistency, at least in  
17 generic cases. We have had a few specific cases that  
18 we've used where we built on the models that currently  
19 existed, and went out and collected more specific data  
20 according to that case-specific issue.

21 Some of these that I'd like to mention,  
22 one currently we have a petition for rulemaking  
23 regarding irradiators, and the issue at hand is a  
24 reduction in the amount of oversight by a trained  
25 operator.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           So, instead of just relying upon the  
2           educated guesses of the people who developed the  
3           earlier models, we went out to look at several  
4           facilities to see how close were our engineering  
5           judgments to the real world. We collected specific  
6           data. And that's probably the approach we will take  
7           in other issues of this type.

8           Materials inspection program review. We  
9           used the information from NUREG 6642 to address issues  
10          of dose, worst possible consequence, other things that  
11          you can use 6642 with, but we used also a risk-  
12          informed approach. We didn't rely mainly on that  
13          information. We also had a number of seasoned  
14          individuals who knew the material well and could tell  
15          just from their experience whether or not the data  
16          really supported reality, or whether reality supported  
17          the data.

18          I'm not too familiar with the in-situ  
19          leach facility study, but I suppose that's the same  
20          issue. The Trojan Reactor Vessel shipment is one  
21          where not only did they look at the generic case, but  
22          they addressed specific weaknesses that existed for  
23          that type of shipment, such as controlling how high  
24          the canister or the reactor vessel could be raised  
25          above the ground on the road towards its ultimate

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 repository.

2 Those are cases where you take the generic  
3 to get sort of a field idea of how big is the issue,  
4 what are the things I need to consider, and then when  
5 you decide you want to tackle it, you can go in and  
6 get specific data.

7 (Slide.)

8 I guess what I'd like to say as far as --  
9 it's kind of difficult to say that this is all process  
10 improvements because these are ideas that we gained  
11 from the case studies and some of our work that point  
12 us in the direction of where process improvements can  
13 be. I think Jim Danna will address these in just a  
14 minute. But we've learned that a single safety goal  
15 such as exists with NRR, not very possible here in  
16 this area. I mean, we could try to force it, but  
17 there are too many issues, too many considerations  
18 outside of chances of core melt that we have to worry  
19 about. The big one, again, is to recognize that zero  
20 is impossible in the real world. The only way to  
21 actually have a zero-probability of something  
22 occurring is to make sure that that activity never  
23 takes place where you preclude any accidents, any  
24 events that might lead you to the wrong path. But the  
25 fact is, we've been told by the Atomic Energy Act to

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 license these materials, so we have to take into  
2 consideration that there is a certain probability that  
3 a failure to follow administrative detail will occur,  
4 and we will have to deal with that consequence.

5 And, again, we need to address the human  
6 reliability issue, and it needs to be done in an  
7 approach that is consistent across-the-board, and also  
8 is credible, transparent, defensible -- I think is one  
9 of the words I heard earlier -- where we can put the  
10 numbers down and have some confidence that not only  
11 are they right, but won't have much opposition to  
12 them.

13 That's it for my set of slides. I'd like  
14 to introduce James Danna, who is going to tell us what  
15 we are going to do in the future to solve all these  
16 issues.

17 MR. DANNA: My name is Jim Danna. I'm a  
18 Systems Performance Analyst with the Risk Task Group.  
19 For the next few minutes I'll briefly discuss the next  
20 steps of NMSS to risk-informed regulatory activities.  
21 I'll refer to these next steps as Phase 2.

22 (Slide.)

23 We can consider our efforts and activities  
24 to develop a process to risk-inform in the materials  
25 and waste regulatory areas to date as Phase 1. Many of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 you have been involved with Phase 1 activities. Phase  
2 1 has included the development of the case study  
3 approach and plan, the conduct of the eight case  
4 studies, and the development of the screening  
5 considerations.

6 Phase 1 also included the development and  
7 implementation of a training program for NMSS staff  
8 that focused on risk, risk assessment, risk  
9 management, and risk communication.

10 Finally, Phase 1 also included the initial  
11 consideration of the feasibility and utility of safety  
12 goals for materials and waste regulation. The  
13 previous speakers have discussed most of these  
14 activities.

15 In Phase 2, we plan to apply what we have  
16 learned in Phase 1 to accomplish and to move forward  
17 with risk-informing materials and waste regulatory  
18 activities. In Phase 2, we will systematically review  
19 the regulatory applications for which NMSS is  
20 responsible, to apply the screening considerations,  
21 and initially identify those areas where risk-  
22 informing may be potentially beneficial and feasible.

23 (Slide.)

24 The basis for Phase 2 is provided in  
25 Commission paper SECY-99-100 titled Framework for

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Risk-Informed Regulations in the Office of Nuclear  
2 Materials Safety and Safeguards. This is dated March  
3 1999. Marissa mentioned this Commission paper earlier  
4 in her presentation. In SECY-99-100, the staff  
5 presented to the Commission, at its request, a  
6 framework for risk-informing materials and waste  
7 regulation similar to the framework developed earlier  
8 for reactor regulation. The staff also presented a  
9 process for implementing the framework.

10 As the first part of the framework, the  
11 staff proposed to define the regulatory areas where  
12 risk assessment methods could play a role in the  
13 regulatory decisionmaking process. These would be  
14 areas where a regulatory process might benefit from  
15 using risk insights and information.

16 To implement this first step of the  
17 framework, the staff proposed to identify candidate  
18 regulatory applications where risk insights and  
19 information could play a role in the regulatory  
20 process and where a benefit may be realized.

21 (Slide.)

22 Phase 1, the case studies, the development  
23 of screening considerations, the development of the  
24 staff training program, and the evaluation of the  
25 feasibility of safety goals was NMSS' initial effort

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 towards identifying regulatory areas and applications  
2 amenable to being risk-informed.

3 Phase 2 will be the NMSS effort to  
4 complete this initial identification. Here is the  
5 general approach we are proposing for Phase 2. The  
6 first step will be to develop a written plan for Phase  
7 2 that describes the approach, the product, and the  
8 schedule for implementation. This will ensure that  
9 the scope and level of detail of Phase 2 is clearly  
10 defined and understood.

11 Next, the staff will systematically  
12 identify the general regulatory activities of NMSS.  
13 We will likely use the regulations as a starting point  
14 to define the NMSS regulatory universe, if you will.  
15 And we will use the current NMSS operating plans to  
16 describe what we actually do on a day-to-day basis.

17 Once this is initially completed, we will  
18 likely identify and set aside certain areas from  
19 further consideration at this time. These may be  
20 regulatory areas that have recently been revised or  
21 that are currently considered to be adequately risk-  
22 informed. Examples may be activities associated with  
23 fuel cycle facilities, medical applications, and the  
24 high-level waste program.

25 We will then categorize and bin the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 remaining activities as appropriate for efficiency.  
2 And, finally, we will make a first attempt at applying  
3 the screening considerations. In applying the  
4 screening considerations, the staff will follow the  
5 guidance that will be developed as discussed earlier  
6 by Raeann. We will also rely on the experience and  
7 insights gained through the case studies and through  
8 the other risk initiatives and activities that NMSS  
9 has undertaken to date. And, of course, we will  
10 consult with NMSS management and the staff and other  
11 stakeholders throughout this process.

12 (Slide.)

13 The expected product of Phase 2 will be an  
14 initial set of potential NMSS risk initiatives. These  
15 initiatives would be the regulatory application areas  
16 defined in a general way, where a risk-informed  
17 approach or modification may further the Agency's  
18 strategic and performance goals.

19 In terms of safety, increased public  
20 confidence, increase regulatory effectiveness and  
21 efficiency, and reduce regulatory burden and, where we  
22 feel it would not be likely prohibited by technical  
23 feasibility, cost effectiveness, or other factors.

24 (Slide.)

25 We would document the Phase 2 effort and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 results by presenting the potential NMSS risk  
2 initiatives and the basis for their identification.  
3 This would likely be expressed in terms of the  
4 screening considerations, and would describe the  
5 factors and issues reflected in the initial  
6 application of the screening considerations.

7 The documentation would also identify and  
8 provide the basis for the areas initially set aside or  
9 initially screened out. We feel that documenting the  
10 Phase 2 effort in this way will allow others to review  
11 the factors that were considered for each of the  
12 materials and waste regulatory areas in applying the  
13 screen considerations. This way, management, staff  
14 and other stakeholders will be able to review and  
15 revisit these considerations and determine whether or  
16 not they would hold up in the future, or they may be  
17 reconsidered.

18 (Slide.)

19 After Phase 2, potential risk initiatives  
20 identified through Phase 2 would be prioritized  
21 through the existing NRC planning, budgeting and  
22 performance management process, the PBPM process. The  
23 higher priority initiatives would be identified for  
24 further near-term consideration. Staff within the  
25 responsible NMSS divisions would continue to

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 investigate and develop the risk-informed approaches  
2 or modifications. This would be considered Phase 3,  
3 the actual modification and implementation process.  
4 It is expected that as the individual risk initiatives  
5 are explored, the screening considerations will be  
6 revisited and reconsidered.

7 (Slide.)

8 As many of you know, up to this point the  
9 staff has been risk-informing specific regulatory  
10 processes within the nuclear materials and waste  
11 safety arenas, in parallel with our efforts of Phase  
12 1. The case studies and the development of the  
13 screening criteria are two examples.

14 The staff will continue with risk-  
15 informing specific regulatory processes on a case-by-  
16 case basis in parallel with the Phase 2 activities.  
17 Staff's experience to date with risk-informed  
18 initiatives and activities will be factored into the  
19 Phase 2 process. It is expected that the Phase 2  
20 effort will benefit greatly from this experience.

21 Note that the identification of potential  
22 risk initiatives through the Phase 2 process will  
23 complement the existing avenues for identifying  
24 regulatory initiatives. As many of you know, these  
25 existing avenues include operating experience,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 direction from the Commission, or proposals from  
2 stakeholders and staff.

3 Also note that safety goals for the  
4 materials and waste safety arenas, as discussed, and,  
5 finally, if found to be desired, will also be  
6 developed in parallel with the Phase 2 effort.

7 That concludes my comments on where we  
8 plan to go from here, and I thank you for your  
9 attention. I think Marissa has some concluding  
10 remarks, or Lawrence.

11 MR. KOKAJKO: Thank you, Jim. I'd like to  
12 thank everyone for their informative and succinct  
13 presentations today. Our purpose was to try to get as  
14 much information out in the shortest possible time, so  
15 that we can start having some interactions with the  
16 stakeholders.

17 We really do want your input today, and we  
18 want to hear from a variety of people and views. What  
19 we've presented today is what we think are appropriate  
20 things to do, what we derived from the case studies,  
21 and by no means are we set in concrete on many of  
22 these matters. We really do need your input on what  
23 we have done and what we should do further.

24 (Slide.)

25 Let me summarize where we briefly are.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Screening considerations seem to work well. They were  
2 tested in the case studies, and I have to tell you  
3 they have also been tested in some other applications,  
4 as I think Jim Smith mentioned, and they do seem to  
5 work. We would like to get your input on the  
6 application of them and what guidance might be useful  
7 to make them work even better.

8 Value-added process improvements can be  
9 made, but we would like your thoughts on this,  
10 particularly we would like to understand what you  
11 think we might do, what programs we might look at,  
12 what particular applications of the regulatory  
13 framework might be good to look at, and in what areas.

14 I would like to point out at this time, in  
15 case you have thought of this, that during the actual  
16 eight case studies work, we did not identify any areas  
17 within the current framework that would require an  
18 increase in regulatory requirements for that  
19 particular case study, although we did identify  
20 beneficial use of risk information and process  
21 improvements as a result of that. We didn't think  
22 that there would be any increase in regulatory  
23 requirements for that case study.

24 Finally, we think safety goals are  
25 feasible, and they could be helpful, but we would like

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 your stakeholder input on the value and utility of  
2 doing further work on safety goals. We would like  
3 your views on if you think that it's worthwhile and,  
4 if so, what can you tell us about what they might look  
5 like and what they might be used for.

6 This concludes the staff's portion of the  
7 presentation today. From now on, it will be a  
8 facilitated discussion with Dr. Rathbun to help us get  
9 your feedback and input. I would like to have this as  
10 an open exchange of conversation as possible. I would  
11 like to have some dialogue between members of the  
12 staff as well as our subject matter experts who are  
13 here, some of whom cannot be here and participate as  
14 fully as I would like today, due to the handling of  
15 events after September 11th.

16 With that in mind, Dr. Rathbun, would you  
17 please take over?

18 DR. RATHBUN: My name is Pat Rathbun, and  
19 my background is in social psychology and in  
20 statistics. And, basically, I'd like to work with you  
21 the rest of the day to kind of go over what the panel  
22 has discussed and get your specific ideas for input.  
23 I believe we have some questions on a slide.

24 These are the general areas. What are the  
25 factors that we should put into the guidance? What

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 should we think about as we develop that guidance for  
2 those screening criteria?

3 We came up with some ideas for process  
4 improvement but, frankly, we really need your help in  
5 that area. The value and need for safety goals.  
6 You've heard, I think, an outstanding discussion, but  
7 this is a very complex area, so we are looking to you  
8 for that. I see lots of people in the audience who  
9 have had many years of experience with safety goals.

10 And then, finally, after we have gone  
11 through that, we do want to take a hard look at the  
12 future direction of our program and where we are  
13 going. Okay.

14 All right. Under the guidance development  
15 -- let me say this. Before I take these questions,  
16 are there any general areas that you all would like to  
17 share with us before we go into specifically asking  
18 you things? Are there general comments or questions  
19 that you would like to give now? The only rule here  
20 is that you give your name before you speak, so that  
21 the Transcriber can get the right words with the right  
22 person.

23 QUESTION: My name is John Carter, and in  
24 a very general sense, I think the discussion of safety  
25 goals is commendable and very worthwhile, but I have

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 some concerns about the whole nature of the risk-based  
2 regulation discussion because, based on the last  
3 comment that was made, it appears that the risk-based  
4 regulation is really a way to go about deregulating  
5 certain areas that are already regulated. So, we are  
6 talking about a lessening of the regulation, not an  
7 increase in regulation, as is evidenced through the  
8 comment that none of the case study areas will result  
9 in greater regulation. And to me, that is fairly well  
10 known.

11 But I have a concern also as to, again, in  
12 a very general sense, the framework and the sphere  
13 within which this regulatory process will take place  
14 because I think the concern that I have is that there  
15 are a lot of areas of radiation and radioactive  
16 materials that are not regulated under current  
17 regulations, that perhaps the Commission and this  
18 group would want to consider, such as -- and there was  
19 a reference in the materials to the uneven regulatory  
20 scheme now in effect for byproduct materials. There  
21 is this area of pre-'78 non-11(e)2 material, not  
22 regulated. There is NORM material, some of which has  
23 greater radioactive dangers, health and safety and  
24 environmental risks in many regulated materials.  
25 There's the area of unimportant quantities of source

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 material, again, unregulated. And I don't see that  
2 this process is going to address any of those areas.  
3 And maybe that's completely outside the scope, but  
4 those are some of the concerns, some of the issues  
5 that I would like to see addressed. Thank you.

6 DR. RATHBUN: Thank you, John. Lawrence,  
7 did you want to address that?

8 MR. KOKAJKO: I think some of the things  
9 that you've mentioned I think a number of us may have  
10 to respond to. We are not saying our program is risk-  
11 based. We are not looking at making a risk-based  
12 program where you do calculations and come up with a  
13 number and you say that's the answer. We'd like to  
14 think that we're risk-informed. We're using different  
15 assessment techniques and strategies to help us arrive  
16 at a better conclusion.

17 Also, when I mentioned that the eight case  
18 studies did not identify any increase in regulatory  
19 requirements for these eight case studies, that is  
20 true. We thought the framework was sufficient in  
21 staff, the way they manipulated the information to  
22 arrive at their conclusions was adequate. That  
23 doesn't mean to say that there could not have been  
24 other areas where we think that it could be increased  
25 or maybe even decreased. In fact, we would anticipate

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 that.

2 You mentioned a byproduct material and  
3 perhaps the uneven framework for certain things.  
4 NUREG 1717 does talk about that, which Jim Smith, I  
5 think, mentioned earlier. There is a working group  
6 that has been formed to look at that right now. Also,  
7 there has been a materials review that has looked at  
8 some of the inconsistent treatment but not only in the  
9 licensing end, but also in the inspection end as well.

10 And that perhaps leads me to my final  
11 point, which is when we say we're changing the  
12 regulatory framework, we are looking at it very  
13 broadly. We are looking at it in terms of rulemaking,  
14 rules and regs, of course, but also in terms of  
15 licensing processes and guidance, inspection processes  
16 and guidance, enforcement, all of those four things  
17 are part of the framework, and all we think have the  
18 potential to be more risk-informed than they currently  
19 are. While we would like to say that we have enough  
20 information to risk-inform everything, I just don't  
21 think that's true. And that there is a double-edge to  
22 this. You could risk-inform and find out that maybe  
23 you're being too restrictive in some areas. In other  
24 areas, you may find out that you need to be more  
25 restrictive. And we are open to both possibilities.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. RATHBUN: Does anybody else want to  
2 address the whole idea of what's in and what's out,  
3 and what we do about those areas that we don't  
4 regulate now, such as NORM. Dennis?

5 DR. DAMON: This is Dennis Damon. I had  
6 a piece of information to pass on. I do not know what  
7 the Commission's reaction to the idea that the work  
8 that's being done here might lead to an expansion to  
9 the scope of what is regulated in general, beyond  
10 simply expanding the scope within the context of the  
11 existing Atomic Energy Act and regulations. However,  
12 there was an interesting study coming out of NCRP,  
13 which I can never remember the exact -- National  
14 Council on Radiation Protection -- and in that study  
15 it attempted to lay out a systematic way of  
16 identifying waste based purely on risk considerations,  
17 both chemical and radiological risk, and not on where  
18 that waste came from, which is the current -- if you  
19 look at the current Atomic Energy Act, this Agency is  
20 -- the scope of this Agency is based on where the  
21 material came from because it originated during the  
22 days when the Government had all the nuclear material  
23 for the purposes of making bombs, and it was trying to  
24 transition to using this material for civilian uses.  
25 And this new study backs off from that and takes a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 more global view and says let's just look at waste,  
2 regardless of where it came from, but just look at  
3 what's dangerous about it and how you should manage  
4 it.

5 And so what I suspect is true is that if  
6 we investigate the rational structure behind safety  
7 goals, we will be creating a structure which will lead  
8 you to the same kind of conclusions, namely, it  
9 doesn't pay any attention to the current regulatory  
10 structure or the law, it is only looking at the risk.  
11 And so that conclusion will be implicit in the  
12 information structure that you create, just like the  
13 NCRP thing was. But whether the Commission or the  
14 staff, management of the Agency, is interested in  
15 addressing changes to that, to the scope of their  
16 work, is a broader question.

17 The risk information will be there for  
18 them to use, and that's what the difference is between  
19 risk-based and risk-informed.

20 DR. RATHBUN: Thank you, Dennis. Does  
21 that answer your question, John?

22 MR. CARTER: Yes.

23 DR. RATHBUN: Okay.

24 QUESTION: My name is Cal Ozaki, and I was  
25 really interested in your comment about the NCRP

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 because one of the questions I have regarding what the  
2 NRC is doing here is, it seems like this could be  
3 directly applicable also to other agencies' work, such  
4 as Department of Energy and how they regulate their  
5 materials and activities.

6 So, I was wondering what type of  
7 collaborative effort or communication you at the NRC  
8 are having with folks in the DOE that may be pursuing  
9 similar types of risk-informed regulations.

10 DR. RATHBUN: Lawrence?

11 MR. KOKAJKO: First, as you know, Bob Bari  
12 and Vinod Mubayi are from Brookhaven National  
13 Laboratory. They have a number of contacts, and I  
14 know they have been discussing things with others.

15 The other day I received a call from  
16 Argonne from someone who was interested in some of our  
17 information today, and I know we've had DOE  
18 participants at our stakeholder meetings. We try to  
19 get as widely attended gathering as possible to  
20 discuss what we are doing.

21 Specifically, we have not asked DOE to  
22 come in here just to meet with us on these topics.  
23 Perhaps as time goes on and as we move a little  
24 further along, we'll be able to maybe have some of  
25 those discussions, but hopefully this suffices for

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 that type of interaction and then on an as-needed  
2 basis.

3 DR. RATHBUN: I think there are a number  
4 of people from DOE here.

5 QUESTION: I'm Maggie Sturdivant, and I am  
6 from the Department of Energy. We have been working  
7 -- Bob can tell us how many years now on risk-informed  
8 approaches to doing work, particularly with waste  
9 management.

10 DR. RATHBUN: Okay. Any other questions  
11 or comments here?

12 QUESTION: Melanie Galloway. I was hoping  
13 you could explain in a little bit more detail the  
14 reason for the change from screening criteria to  
15 screening considerations, and whether or not there is  
16 any implication there for the rigor with which the  
17 staff should apply these now-called considerations, or  
18 the scope of the situations in which we should apply  
19 them?

20 MR. KOKAJKO: I will let Raeann take that,  
21 but before I do, one of the big reasons that we found  
22 was that people began to look at the screening  
23 criteria as yes/no, go/no-go type statements, and they  
24 are not. People began to think in terms of, well, if  
25 you said yes to everything, then you were to do it,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 and that wasn't the case at all. It was meant to be  
2 just one tool in the management kit bag, if you will,  
3 that they could pull out and try to use, rather than  
4 if you came up to a yes, you had to do it. We felt it  
5 was confusing to the staff as well as to management  
6 about what the purpose was.

7 We also know that the performance-based  
8 paper that was approved by the Commission back in '98  
9 or '99, they called the performance-based items  
10 "considerations" as well. So, in order to conform  
11 with that, we decided to call them considerations.

12 DR. RATHBUN: Did you want to add to that  
13 Raeann?

14 MS. SHANE: I think that was a pretty good  
15 summary.

16 DR. RATHBUN: Thank you. Melanie, does  
17 that answer your question?

18 MS. GALLOWAY: It answered the first part,  
19 but not the second. I was asking as a second part as  
20 to whether or not that means that there's any change  
21 in the way that we apply them.

22 MR. KOKAJKO: In terms of application, I  
23 don't think so because I still think you will tend to  
24 go about, you know, trying to look at the thing that  
25 you are interested in looking at, apply the criteria

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 as you see it, and then it is just now another input  
2 to management to make a decision on whether or not to  
3 proceed or not to proceed.

4 It comes down to a risk-management  
5 decision. If they want to continue with it, this  
6 appears to amenable for further work, that's okay.  
7 They may not want to do it, or the criteria itself may  
8 say, hey, this is not amenable, you ought to not  
9 pursue this particular approach anymore.

10 DR. DAMON: This is Dennis Damon. I'd  
11 just like to make a comment about this. I kind of  
12 have somewhat of an alternative, supplementary  
13 perspective on this, and that is, the screening  
14 criteria, in one sense, are a lot simpler than what  
15 they may appear to be. It looks like some complicated  
16 thing you go through.

17 All we're trying to do is get you to ask  
18 the question, what are you going to use the risk  
19 information for if you have somebody calculate it? In  
20 other words, don't hire somebody to do a study for you  
21 and calculate something before you figure out what you  
22 are going to use the information for. And then you  
23 have to add to that sort of the obvious thing. If  
24 there is some obvious -- if you don't have the money  
25 to do the study, then don't propose that it be done.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 So, those type of things are imbedded in there, but  
2 they are kind of obvious things.

3 The idea is, figure out why you want a  
4 risk study done, what decision are you going to  
5 address, before you start, because if you just tell  
6 somebody, go do a risk study, they will do one,  
7 they'll come back and you say, gee, that wasn't what  
8 I wanted. That doesn't help me with the problem I  
9 have. So, you have to define your problem first.

10 I'll give you an example. The irradiator  
11 risk study, the question they wanted answered was --  
12 it was a proposed petition that Jim Smith referred to.  
13 The petition came in and said the licensees would like  
14 to have the option of not having an operator present  
15 at the irradiator facility 24-hours-a-day whenever it  
16 was operating. Now, that means that it would have an  
17 irradiator running there for part of the day with no  
18 operator present.

19 So, the risk study was done, and they had  
20 to calculate two risk numbers. What is the risk of  
21 the irradiator, if it is operated with an operator,  
22 and then what is the risk if it is operated part of  
23 the time without an operator. So, if you don't define  
24 that question before you ask for the risk study, they  
25 won't calculate the information that you need to make

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the regulatory decision.

2 So, that's all the screening criteria are  
3 about, is just common sense and do you have the money  
4 to do the study. Is there some law that would have to  
5 be changed, which you don't think anybody is going to  
6 change? It's really quite simple in that sense.

7 The other option, though, is it is  
8 actually more complicated because when you are  
9 applying the screening process, you don't know what  
10 the answer is going to be. You don't have the risk  
11 information. The risk -- it's hard to estimate the  
12 cost of risk studies very often. You haven't actually  
13 had somebody do a quantitative analysis to know what  
14 the cost savings are going to be, as to whether there  
15 is burden reduction or if the staff efficiency  
16 improvement and stuff like that. So, you are kind of  
17 making an a priori guess as to whether this is going  
18 to save staff time or reduce burden and stuff, and  
19 this risk information will help you make the decision.

20 DR. RATHBUN: Bobby.

21 QUESTION: My name is Bobby Eid. I have  
22 two questions, one question regarding ALARA, which is  
23 as low as reasonably achievable, and how it fits in  
24 the safety goals. That is my first question. Would  
25 you like to answer that?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. RATHBUN: Why don't you go ahead and  
2 say both questions, and then they know kind of who to  
3 field it.

4 MR. EID: The second question is  
5 specifically to Dr. Bari, about the quantifying  
6 environment of risk, and what is your approach for  
7 quantifying environmental risk?

8 DR. BARI: Those are two excellent  
9 questions, and we would very much like to get input  
10 from people here on how to go about those. With  
11 regard to ALARA, I think it's a very legitimate thing  
12 to consider in framing -- we are not yet at the point  
13 where we could propose something definitive. There  
14 are obviously benefits to invoking an ALARA scheme in  
15 this area. Of course, one does want to fully  
16 recognize the cost involved and the risks that are  
17 being mitigated.

18 Your other question was on the  
19 environmental -- we are in the very early stages of  
20 struggling with one, that is certainly an important  
21 one. I believe at an earlier stakeholder meeting,  
22 there was a comment, in fact, about decommissioning  
23 area in terms of moving dose-fixed contaminants and,  
24 in the process, scarring the earth and leaving behind  
25 environmental damage.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           The question really comes down to, or  
2 maybe it could be framed in terms of what are the  
3 tradeoffs, what are the benefits to be gained, and  
4 what risks are being mitigated. This will be a  
5 difficult area of our discussion. It is our hope that  
6 we can get a better feel for that, going back and re-  
7 examining the case study and additional risk  
8 information, engaging folks in discussion of this  
9 issue, understanding the values of an environmental  
10 goal.

11           MR. MUBAYI: My name is Vinod Mubayi, from  
12 Brookhaven. Let me just add a couple of points to  
13 first safety. Safety goal is really a broader concept  
14 than ALARA. In ALARA, we look at a very specific  
15 process like, for example, how much shielding do we  
16 need to provide in some room consistent with the  
17 workers accomplishing their tasks, and then we can use  
18 some optimization principle to go as far as we think  
19 is reasonably achievable in that specific task. But  
20 the safety goal would encompass a number of -- you  
21 know, would encompass a large number of activities,  
22 like in reactor space, ALARA is usually done for  
23 workers with specific tasks inside the plant, and we  
24 look at specific processes. But the safety goal  
25 applies on a wider scale. It applies to accidents.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 It applies to -- well, ALARA is in the context of  
2 normal operations mostly.

3 As regards your second question, I think  
4 it is a very interesting arena right now when you look  
5 at this environmental goal that one is thinking of,  
6 and what kind of metric will we actually use in terms  
7 of arriving at some quantitative environmental  
8 objective that is consonant or adds value like the  
9 quantitative health objectives in the regulatory  
10 process. And whether it is some sort of contamination  
11 level which then can be translated into a dose level  
12 with some procedure, or whether it is some sort of a  
13 dollar amount that may prove to be a more useful  
14 metric, I don't know right now, but I think we have to  
15 consider a variety of different metrics, apply them,  
16 and then try to understand their implications.

17 DR. RATHBUN: This is probably a good time  
18 to see if there is anybody in the audience who would  
19 like to add to this discussion. Now is your chance.

20 QUESTION: My name is Hugh Evans, AEA  
21 Technology. I believe my questions are going to be  
22 primarily directed towards Jim Smith. The perception  
23 that I have for three of the case studies that involve  
24 sealed radiation sources in gas chromatography, static  
25 eliminators and fixed gauges, is that the risk

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 analysis that has essentially been embodied into the  
2 licensing process by determining fitness for purpose  
3 via the ANSI and ISO tests has minimized risks to a  
4 very good degree. And my question, number one, is, is  
5 this also the conclusion that you have come to from  
6 the case studies to date?

7 And, secondly, you specifically mentioned  
8 the human element as a reference by "are you going to  
9 press the right button today". We are aware of  
10 shortcomings in licensees not carrying out necessary  
11 paperwork, et cetera. Do you believe that there is  
12 any easy way of improving on the human element?

13 MR. SMITH: That's a big question. I'm  
14 not sure that I can answer the second one, but I'll  
15 give it a try. The first one I can only answer for a  
16 gas chromatograph. The conclusion that I came to when  
17 I looked at the regulation as well as the licensing  
18 process and the other regulatory aspects of it, it  
19 greatly exceeds any safety requirement that may come  
20 up as far as a dose limit, either an accident or  
21 operations.

22 I don't believe I can say the same for the  
23 other two you mentioned, static eliminators as well as  
24 fixed gauges. I'd have to leave that to Mr. Danna on  
25 my left and Ms. Shane on my right.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           The other issue with respect to  
2 reliability, I'm not sure at this point where to go  
3 with that. I just recognize that we have done several  
4 risk studies, and always the Achilles' heel for these  
5 types of studies are you are relying upon a guess as  
6 to how precise or how accurate or how reliable an  
7 individual will do a certain task because almost all  
8 of the materials areas rely upon human beings to do  
9 things. It's not a very engineered process to  
10 radiograph something, a source out of a shielded box  
11 and it sits there in front of a piece of gum for a  
12 period of time. Really and truly, a human being is  
13 controlling all the safety aspects.

14           I don't think that an engineer can come up  
15 with a prediction, they'd probably do some sort of  
16 study of past events and come up with what has  
17 happened before. I don't think you can predict what  
18 will happen in the future.

19           We do have a lot of licensees out there of  
20 these types, so I think that if you could mess it up,  
21 sometime in the past, most of our licensees have done  
22 that, but I'm not sure that they have done away with  
23 all the options for messing up. I'm sure that there  
24 are new and brighter ways to become exposed to  
25 radiation that they are going to come up with in the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 future.

2 DR. RATHBUN: Okay. Anybody else?

3 MR. KOKAJKO: I think Raeann and Jim need  
4 to also respond.

5 MS. SHANE: If I remember your first  
6 question right, do we think the review standards have  
7 made these devices safe, and I would agree with that.  
8 I think major changes -- at least I'm talking about  
9 the fixed gauges study now -- perhaps it's our  
10 application of our licensing policy as far as which  
11 categories gauges would fall into that could benefit  
12 from some risk information. Currently, we have very  
13 similar devices regulated in very different ways, and  
14 I'd like to see that become more consistent some risk  
15 information.

16 MR. DANNA: With respect to static  
17 eliminators, I think in conducting the case study I  
18 found that your assertion is also correct, that --  
19 think of it as a two-step process, it is actually the  
20 certification of the sealed source itself, which is  
21 the design which is held to the standards. That  
22 ensures the integrity and the containment of the  
23 byproduct material. The certification of the device  
24 ensures that the sealed source -- tampering with the  
25 sealed source is reduced, greatly reduced, or

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 prevented, and that is verified through the return of  
2 the device and verification that the device integrity  
3 has not been jeopardized. So, I think your assertion  
4 is correct.

5 DR. RATHBUN: Okay. Thank you. Dr.  
6 Pavlova, did you want to add to that?

7 QUESTION: Maria Pavlova, Department of  
8 Energy, Office of Health Status. What I would like to  
9 address is the important question about the human  
10 element. And I think going into that, we have to  
11 approach the whole process of risk assessment, risk  
12 management, and the risk communication that is a must.  
13 I don't know how many of you are familiar with our --  
14 in 1997, there came a report from the congressional  
15 committee under the National Academy of Science that  
16 deals with the risk management process. And one of  
17 the most important principles there is that the  
18 stakeholders take a central part so that whether you  
19 identify a hazard or a problem or risk, and then you  
20 go through quantity or quality of this risk and what  
21 are the options to deal with this, and what is the  
22 evaluation on the effectiveness of what you have done.  
23 In all of those stages, one has to involve  
24 stakeholder.

25 I have been coming to those meetings of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the Commission for sometime, and myself, as a person  
2 that has been involved in risk communication for at  
3 least 15 years, I am very impressed with the progress  
4 that you have made, and the sincerity in what you do  
5 regardless of how difficult it is.

6 When we talk about the human factor, at  
7 DOE, as my colleagues you probably very well know, at  
8 the moment we have a chemical safety analysis. We  
9 technical people seem to talk more about analysis  
10 safety, and yet we do not think that this safety  
11 relates to worker or relates to community, relates to  
12 humans.

13 And I was fortunate to be involved in a  
14 health risk communication dealing safely with  
15 beryllium at the DOE sites, had three pilots with  
16 that, and find out how important it is that the human  
17 element, if they are occupational, in the workplace,  
18 are made aware, have been educated, have been  
19 motivated, and this is done only with the main purpose  
20 of making them involved.

21 So, it is not only regulation from the top  
22 and out or not, but how much they will participate in  
23 the whole process. And with this particular approach,  
24 we were able to have a task force of six people, but  
25 the driving source were the workers, the people

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 involved together with the managers and the technical  
2 people.

3 So, in this -- I don't want to be too  
4 long, I know you have --

5 DR. RATHBUN: That's okay, I was just  
6 moving toward my coffee.

7 DR. PAVLOVA: You always have it very  
8 close, that's good. And we have had discussions  
9 particularly with Lawrence and our colleagues from  
10 Brookhaven National Laboratory, and I talked with  
11 Marissa, you are trying to get to some practical  
12 guiding document. It is very important to do so.

13 So, I see at least two different type of  
14 audiences. One is your own, and then you can use a  
15 little more technical language as it has been today.  
16 As a physician, though, I have worked with EPA and now  
17 the DOE, sometimes have a hard time understanding what  
18 you mean by that. And I can imagine how the workers  
19 or how the community around, who are very concerned,  
20 understand that.

21 So, my suggestion will be that whatever  
22 you do, try to have at least two versions, one maybe  
23 for your managers and your stakeholders because you  
24 have quite a few stakeholders. I understand some are  
25 of the quality of the gentleman who sounded very

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 highly technically educated -- I forget your name --  
2 but I am always very much impressed with people that  
3 communicate like the colleagues from Brookhaven, in a  
4 language that shows a lot of knowledge. So, you have  
5 these stakeholders.

6 But then within these stakeholders, you  
7 have their workers and you have the communities  
8 around. So, I find it very useful to have a smaller,  
9 perhaps, guiding document in which it is done with  
10 involvement of workers. Let them do it in the  
11 outline. Let them peer review it through their own,  
12 and make a focus group of the community so that the  
13 involvement of the people that are concerned will be  
14 there, and then they can sell either good sense to  
15 their peers what we are trying to do together because  
16 there is no question that their trust among them is  
17 much higher than the trust that we unfortunately have  
18 as government nucleus. Thank you.

19 DR. RATHBUN: Thank you. How about --  
20 anybody else here?

21 (No response.)

22 Okay. As we move into this next stage,  
23 I'm going to be joined at the front of the room by Ms.  
24 Christiana Lui. She is one of the really long-  
25 standing members of the Risk Group, left for a while,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 is now back, and she is going to help me by recording  
2 on the board items that we want to cull out for  
3 special attention.

4 All right. We will return to the more  
5 formal feedback session here, and our first question  
6 is on the guidance development, and just a basic  
7 question, and that is, what additional factors should  
8 we consider in developing our guidance for  
9 implementing the screening considerations? To recall  
10 Raeann's talk, at the bottom of each slide she put up  
11 the types of things that we were beginning to look at,  
12 and now we'd like to turn to you to see if you have  
13 any additional factors. We can even put our slides  
14 back up if you want memory jogging.

15 (No response.)

16 There's always time for later on. Let's  
17 move then to the process improvement area, and what  
18 we'd like to ask you is can you suggest additional  
19 areas for process improvements in the following three  
20 areas. One would be use of the screening  
21 considerations; two, using safety goals consistently,  
22 and in developing and using tools, data and methods.  
23 Do we have any feedback on that area?

24 (No response.)

25 Now, come on, we're not perfect here.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1           MR. KOKAJKO: I would be interested in  
2 knowing -- you saw the eight case studies out front.  
3 Those were our first pick, and that was based  
4 primarily on input from division directors which  
5 compose the NMSS Risk Subcommittee. And, clearly, we  
6 cannot take all of NMSS on at one time. We need some  
7 -- to see if you guys have some ideas about which  
8 would be a better -- there are some things in NMSS  
9 that need to be taken a look at now. I know that a  
10 couple of comments earlier were that there may be some  
11 inconsistent regulatory approaches in some of the  
12 byproduct material. Do people have a sense of some  
13 examples of that, and what it might be, what it might  
14 look like, and also if there's any proposed changes or  
15 processes that you would recommend. And I know we  
16 have staff here, and it would be a great time for  
17 staff to come up with some ideas as well. I know that  
18 they've been around here for a while, and I know that  
19 they've probably seen areas that could be improved  
20 upon.

21           QUESTION: My name is Paul Goranson. You  
22 were mentioning about the consistency of regulations  
23 on byproduct material. I think that one of the  
24 challenges I see ahead -- technical issues aside, the  
25 legal definition of what is byproduct material and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 what isn't. Earlier somebody mentioned about the pre-  
2 1978 byproduct material and the current byproduct  
3 material which is regulated now by NRC. Those are the  
4 type of inconsistencies that occur which make it  
5 difficult for a licensee, who is either accepting  
6 byproduct material for disposal or has received in the  
7 past byproduct material for disposal that suddenly has  
8 come into question.

9           Secondly, there is quite a bit of material  
10 out there that's kind of in a licensing as to what the  
11 status is, it's still relatively questionable. So, if  
12 you're going to look at that type of direction would  
13 probably be a good place to look that may give the  
14 Commission better guidance on how they ought to  
15 regulate that material.

16           DR. BARI: I think that's a very good  
17 point. A risk-informed approach would be very helpful  
18 here. It will look at the hazards being posed by the  
19 byproduct materials, and also where they are going.  
20 Where they are going is already a fairly high hazard  
21 environment and contamination that's being added or  
22 introduced in very small increments.

23           MR. GORANSON: Well, I guess a follow-on  
24 to that is you have some material that's going to RCRA  
25 sites which have different criteria to material that's

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 going to a byproduct disposal site which falls under  
2 Part 40. There's two entirely different criteria, and  
3 the risks are the same, the materials are the same,  
4 they are the same but you have two different criteria  
5 all because of the legal definition.

6 DR. BARI: I believe that this is an  
7 opportunity to make the process more rational.

8 DR. RATHBUN: Did you want to add to that,  
9 Jim?

10 MR. DANNA: Yes. I believe that this  
11 issue sort of relates to question 7, screening  
12 considerations. There are issues that we can deal with  
13 as a regulatory body, and then there are issues that  
14 are outside of our realm, such as legislative issues.  
15 And the reason why those materials are treated  
16 differently is not based upon a risk analysis  
17 difference, more or less, because it was mandated to  
18 do that through law.

19 I mean, like Dennis said earlier, there  
20 are some laws that we may be able to impact to change,  
21 but they are not within our ability to -- we can't  
22 sidestep them to write our regulations.

23 DR. RATHBUN: I think we have a question  
24 from Joe Murphy.

25 QUESTION: I'm Joe Murphy, and I'm with

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the Office of Research, and I've been playing in the  
2 area of safety goals and things like that for reactor  
3 space. Very complex issue.

4 As I sat and listened to your discussion,  
5 a couple of general thoughts came to mind that I'd  
6 like to share with you. One is that you have a big  
7 advantage that I don't think you realize, and that is  
8 that in the kind of things that are regulated by NMSS  
9 already have probably the best risk-informed,  
10 performance-based regulation known to the NRC. That  
11 is know as Part 20. Part 20 is definitely a  
12 performance-based regulation. It may be the only good  
13 performance-based regulation that we have. And it is  
14 definitely risk-informed, the way the numbers were  
15 picked.

16 So, you are starting from the standpoint  
17 of your basic regulation, one that is performance-  
18 based and risk-informed. You already have -- you are  
19 not shifting to a risk-informed approach, you already  
20 started with one. And now what you're trying to do is  
21 make it better.

22 One of the problems -- and this is true in  
23 reactor space -- more years ago than I like to  
24 remember, I stood before somebody and swore there was  
25 no undue risk to the health and safety of the public

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 in a public hearing. Our regulations back in the '60s  
2 were risk-informed, by our understanding of risk.  
3 What we did not necessarily do is update them as we  
4 got smarter.

5 And so some of them may not be risk-  
6 informed now, or they need to be updated, and I think  
7 you should think of it more in that kind of light.

8 It would help if I opened my notes to the  
9 page. The concept of ALARA is a risk-informed  
10 concept, as low as reasonably achievable. That's what  
11 "reasonably" means, to my way of thinking. Doesn't  
12 say as low as possible, as low as reasonably possible.  
13 You don't force things down to the point where you're  
14 spending billions to clean them up. You go as low as  
15 reasonably achievable.

16 So, the basic philosophy is there. Where  
17 I think safety goals will do you the most good is  
18 helping to realize the basic philosophy that you're  
19 operating under. That certainly isn't true in  
20 reactors. It is difficult for me to point to any rule  
21 that specifically has safety goals in it.

22 It is very easy for me to point to  
23 regulatory guidance in our regulatory analysis  
24 handbook or regulatory analysis guideline that are  
25 based on safety goal principles in the reactor end,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 that tell us how to look at things, what's important,  
2 what isn't and, more important, where the dividing  
3 line is that says not "yes" on one side and "no" on  
4 the other, but you need to think more.

5  
6 In the regulatory analysis guidelines,  
7 this is done by a box, like in a row of boxes that  
8 basically go down a line that says "management  
9 attention needed". It means you've got to think.  
10 There's no magic number. You can't rely on the  
11 numbers.

12 As you get into risk-based, you will get  
13 into exactly the problems I heard earlier. You're  
14 going to run into a complex, legal, technical battle  
15 because I know, I've been in some of the facilities  
16 that are licensed by NMSS. And as I walk around them,  
17 I look, and I say the radiological risk is small, the  
18 chemical risk is longest. That was a gut reaction,  
19 walking around. But if you're looking at the overall  
20 risk to the health and safety of the public, it seems  
21 obvious to me that in some of these facilities the  
22 risk to the public may well be chemical and not  
23 nuclear. Can you solve that problem? No. But you  
24 ought to know it. It affects how you regulate the  
25 radiation end of it if you know that the risk is

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 there. So, you have to understand the components of  
2 risk to really do it right.

3 I would call to your attention some work  
4 that has been done in the U.K. They are, I think,  
5 significantly ahead of us on how they use risk  
6 analysis and the regulation of their various  
7 activities. They have the advantage of having the  
8 Health and Safety Executive, which basically regulates  
9 the health and safety of all aspects of technology in  
10 the U.K., not just reactors. It starts with the kind  
11 of thing we do in NRC and goes down to the regulations  
12 that are put on the local butcher so that he doesn't  
13 cut his fingers off. It is the whole gamut of things.

14 There is a report that was issued within  
15 the last year, and I believe the title is Regulating  
16 Risk, Protecting People. I think it is available --  
17 at least it was available -- from the Health and  
18 Safety Executive Home Page. I would call it to your  
19 attention. It's very good, and it uses a concept very  
20 similar to the safety goal principles that we use in  
21 the reactors, and it is well worth reading.

22 What they did is, about ten years ago they  
23 had a report called The Tolerability of Risk, which  
24 was put out by the NII, Nuclear Inspection  
25 Inspectorate -- I'm not sure what it is --

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 Installations Inspectorate -- and they broaden that  
2 now for everything that is regulated by HSE in this  
3 later report, and it basically takes the principles of  
4 the earlier report and has expanded all aspects of  
5 what's going on under HSE consideration. So, I would  
6 call that to your attention, and I hope I haven't  
7 rambled too much.

8 DR. RATHBUN: Thank you, Joe. Any other  
9 comments, either general or directed at improvements  
10 -- augmenting process improvements?

11 QUESTION: This is Mario Robles. I'd be  
12 interested in knowing where you see the program going.  
13 The case studies are retrospective in nature, looking  
14 at what might have been done or might have been  
15 applicable. Looking prospectively, how is it going to  
16 be applied? Are you thinking pilot programs to kind  
17 of have an example for staff to look at, what guidance  
18 is needed, or are you looking at establishing higher  
19 priorities for initiatives that are risk-informed and  
20 that way providing some benefit for licensees that are  
21 thinking of doing something but think it's not going  
22 to be put on the fast-track, but if it's a risk-  
23 informed initiative -- you know, you kind of get them  
24 to the fore? What are you thinking in that area?

25 One item of particular note, Dr. Bari's

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 presentation noted that risk-informed methods would  
2 have been useful in the certification of the GDPs, and  
3 I just wanted to point out that that's a process that  
4 is ongoing. The certificates are five years in  
5 nature, and the current certificates expire at the end  
6 of 2003, so there is a recertification effort. So, if  
7 the conclusion was that it would have been beneficial,  
8 then I would submit that it would be beneficial in a  
9 recertification activity.

10 DR. RATHBUN: Lawrence or Jim?

11 MR. DANNA: Apparently our plans are to  
12 lay out a framework, to identify the different  
13 regulatory areas, and then as folks like you point out  
14 specific areas to look at, we would plug those in.  
15 Once we identify those areas that may be amenable,  
16 where we could see a benefit and it would be feasible,  
17 then they would be pulled into the ongoing  
18 prioritization process. We wouldn't prioritize  
19 outside of that process. We would integrate that into  
20 the process that currently exists.

21 We hadn't anticipated a pilot program  
22 probably because, as I mentioned, there are, or there  
23 have been, ongoing risk-informed activities. So, it  
24 may not be necessary to begin again with pilot  
25 programs. We have enough experience to look at, a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 number of activities to look at, and those case  
2 studies cover the different areas. We'll pull that  
3 information in to learn from those, and to move ahead  
4 with specific concrete areas where we can risk-inform.

5 DR. RATHBUN: Bob or Dennis, did you want  
6 to talk about GDP and safety goals, or not?

7 DR. DAMON: I have a thought. This is  
8 Dennis Damon. I had a thought. I guess Mr. Robles is  
9 from USEC. When it does come time for  
10 recertification, you might -- or you might now take a  
11 look at Reg Guide 1.174, which is the reactor  
12 regulatory guide that addresses how you use a risk  
13 analysis to justify making a change to your technical  
14 specifications or to your license, or certificate in  
15 your case, which is not clearly a reduction in risk.

16 So, if you are proposing a change to your  
17 license or certificate or to a TechSpec which is  
18 clearly a reduction in risk, there is no need to do a  
19 risk analysis. NRC would probably just simply approve  
20 it.

21 But if you are proposing something where  
22 it's not clear how this affects the risk of a plant,  
23 then Reg Guide 1.174 shows how, over in the reactor  
24 side, they consider risk information in evaluating  
25 whether that change would be acceptable or not. And so

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 that's kind of a prototype that might -- you might be  
2 able to exploit on the NMSS side.

3 DR. BARI: I think your comment is a very  
4 valuable one. I think given that we already have some  
5 of the risk-inform machinery in place for a gaseous  
6 diffusion plant and the seismic upgrade, it would be  
7 a very natural thing as you're going through  
8 recertification, to expand those tools and, in the  
9 first instance, use it to help prioritize your own  
10 efforts in the recertification, and then ultimately to  
11 engage NRC in that process. It's an excellent area,  
12 given the nature of the facility, aging issues that  
13 might come up, which are issues, of course, that you  
14 are very familiar with. I think that's a really great  
15 observation that you make.

16 DR. RATHBUN: I'd like to try for one more  
17 question before lunch.

18 (No response.)

19 All right. Let me consult with Lawrence  
20 and you all here on lunch. We had planned for a long  
21 period of lunch because we have to accommodate lots of  
22 people in the cafeteria. Do you want to shorten lunch  
23 and maybe dismiss the meeting earlier?

24 MR. KOKAJKO: Unfortunately, Pat, a number  
25 of people did come up to me and say that they would be

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 coming back this afternoon and could not attend all,  
2 but portions of today's meeting. So, I think we will  
3 have to reconvene at 1:30, at a minimum.

4 Also, I would like to go into the  
5 discussions a little more on process improvement and  
6 safety goals, if people have some comments on that.  
7 One of the things that we know we did want to talk  
8 about was, besides the process improvements of what  
9 you think we should be looking at next, in our next  
10 steps, but what is -- do people feel that safety goals  
11 are feasible, and what they might look like, if they  
12 would be useful, or should we not even consider that,  
13 the value of continuing the program, you know, what is  
14 the general sense of that. So, I'd like to capture  
15 some of that after lunch.

16 And given the fact that some people may be  
17 coming back, I'd like to have the opportunity for them  
18 to provide some comments at 1:30.

19 DR. RATHBUN: Okay. We will see you all  
20 then at 1:30. Thank you.

21 (Whereupon, at 11:55 a.m., the luncheon  
22 recess was taken.)  
23  
24  
25

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

A-F-T-E-R-N-O-O-N S-E-S-S-I-O-N

(1:35 p.m.)

1  
2  
3 MR. KOKAJKO: Welcome back, everyone. As  
4 anticipated, I see a number of people have not yet  
5 returned from lunch, and although this may make it a  
6 little more intimate setting, we would like to hear  
7 from everybody, if possible.

8 Pat is going to take over the facilitation  
9 again as we were doing before lunch, and I would like  
10 to, in anticipation that some people may have had some  
11 things they wanted to say beforehand but didn't, we  
12 will probably cover the four major objectives again so  
13 that we can try to get the input -- at least ask the  
14 questions one more time to solicit your feedback and  
15 input on what we've done so far, and where we might  
16 go, process improvements, the development if feasible  
17 of safety goals and what they might look like, and  
18 that sort of thing.

19 So, with that in mind, let's get started.

20 Pat.

21 DR. RATHBUN: Just because I'm a  
22 psychologist, they believe I'm not mechanical. They  
23 are probably right.

24 All right. Just to go back to where we  
25 were, I'm going to revisit the question on guidance

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 development, the three areas of process improvement.  
2 For the first time, we will move on into safety goals,  
3 and then on into our view to the future.

4           There's also a couple of other things that  
5 Chris brought up that might be useful to take another  
6 look at, especially if we have new people. What would  
7 be an appropriate environmental safety goal? We  
8 thought we might go back and touch on that again. Are  
9 there ways of improving human reliability? We've  
10 mentioned that it is a very large problem, especially  
11 in materials. And, also, the difference between an  
12 ALARA and a safety goal, that they are not the same.  
13 And then two other issues perhaps to touch upon again,  
14 and that is that 10 CFR Part 20 is risk-informed and  
15 performance-based, and what are the implications of  
16 that for us as we go forward here. And then the  
17 whole picture of updating the regulations.

18           So, if you would bear those in mind, too,  
19 and if you have any additional comments on any of  
20 this, please feel free to speak up.

21           QUESTION: I'm Joe Tenhet, and I'm an RSO  
22 of a facility with about 200 gauges of mixed specific  
23 licenses and general. These are a couple of comments,  
24 so please don't feel obligation to respond.

25           One comment is with regard to general

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 license fixed gauges versus specific. In my very  
2 narrow experience, talking with a few number of  
3 manufacturers, it appears that often there's really no  
4 difference between the two, that it's an identical  
5 gauge, it just doesn't have a label on it. And the  
6 reason that they are offered in both modes is because  
7 smaller facilities, maybe facilities owned by very  
8 large companies but with only one or two gauges, don't  
9 want to go through the trouble of having a specific  
10 license, and are willing to pay somebody to come in on  
11 a rare occasion that a fixed gauge needs to be moved,  
12 but even fixed gauges need to be moved sometimes if  
13 they are tied into your production apparatus or  
14 assembly lines, other businesses need a response to go  
15 out there and move it in 15 minutes or 20 minutes,  
16 rather than have someone fly in from California.

17 So, under those circumstances, the  
18 facility will go through the extra effort of getting  
19 a specific license and training their people to take  
20 care of it, although as an approach it is a little odd  
21 if under some types of failures that have to be  
22 reported, if it is a specific gauge, it has to be  
23 phoned into NRC within 24 hours whereas the identical  
24 unit across the street under a general license it  
25 would have to be in writing to the manufacturer within

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 30 days.

2 The other comment I have is about the  
3 process, and there was a lot of discussion earlier  
4 about the laws and regulations, and it was sort of, in  
5 my opinion, an underlying assumption that once a  
6 regulation was written, that was sort of the end of  
7 the process.

8 I'd like to see some attention or emphasis  
9 placed on actual interpretations and policy as well.  
10 NRC does have its NUREGS and Guides for communicating  
11 policy and interpretations, but as an end-user --  
12 perhaps this is not a fair comparison -- but I can go  
13 to the Websites of OSHA or DOT and I can look up  
14 letters and interpretation that other end-users around  
15 the country have written in -- this is my situation,  
16 this is the rule, how does it apply -- and there will  
17 be a copy of the agency's response. And as an end-  
18 user or licensee, I may, at my own peril, decide that  
19 my situation is the same or sufficiently different to  
20 call my Regional Office, but still there is a wealth  
21 of information out there. And so, it is not just  
22 enough to write the reg, how is it being implemented.  
23 In one region has this interpretation and practice, or  
24 perhaps in writing, how can folks find out about that?  
25 Thank you.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. RATHBUN: Jim, did you want to address  
2 that, some of the things you guys have that you have  
3 not been asked?

4 MR. SMITH: Are you asking this Jim, or  
5 that Jim?

6 DR. RATHBUN: Excuse me. Jim Smith.

7 MR. SMITH: Well, yes, we have identified  
8 the fact that there are some inconsistencies across  
9 the different regions in the way that they regulate  
10 materials. There's also a little bit of inconsistency  
11 across-the-board from Agreement States to the NRC.  
12 Trying to make sure that they are as consistent as  
13 possible, what they call the IMPEP process. We go out  
14 to make sure that everyone is reading from the same  
15 song sheet.

16 Unfortunately, there is always going to be  
17 some practice that is sort of a state-of-the-art, it's  
18 not someone that's following procedure, this is just  
19 the way they've always done it, so you may get some  
20 variation. We try to weed that out during the IMPEP  
21 process.

22 Additionally, those interpretations you  
23 are talking about -- we call them technical assistance  
24 -- you are not just asking for a special  
25 authorization, you are asking for a clarification of

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 regulations. Those are supposed to be provided to all  
2 of the Regions in generic fashion, get enough of the  
3 issue to put together -- they develop a guidance  
4 directive. Currently, 1556 is supposed to be that  
5 guidance, and you pick up the volume that applies to  
6 your program.

7           Again, lots of materials, very subjective.  
8 So it's going to be up to the individual licensee as  
9 to how they deal with it until more concrete guidance  
10 is developed for a particular item.

11           DR. RATHBUN: Does anybody else have  
12 anything more to add to that? Raeann? I don't want  
13 to put you on the spot, but you guys have a lot of  
14 knowledge in that area.

15           MS. SHANE: I think you've done a good job  
16 at capturing some of the quirks of our regulation that  
17 hopefully we can, as we go into Phase 2, maybe start  
18 to try to root those out. It's probably too soon to  
19 promise anything at this point.

20           DR. RATHBUN: Anybody else, any of our  
21 audience who knows of these things?

22           (No response.)

23           Any other general comments?

24           (No response.)

25           All right. Having eaten your lunch and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 taken your nice walk, do we have anymore comments on  
2 what we might put into the guidance? It sounds like  
3 what you're telling us is to be consistent and look at  
4 how we could be more consistent and communicate that  
5 more effectively to the licensees.

6 Any other factors that have occurred to  
7 you that we might want to look at in the guidance  
8 development? Anybody on the panel want to say  
9 something they didn't get to say earlier on this?

10 (No response.)

11 All right. Well, we're going to work from  
12 Raeann's slides then, that will be in Phase 2, and we  
13 will go from there.

14 How about the process improvements? There  
15 were three areas we were looking for your advice on,  
16 and that was the use of the screening considerations,  
17 using safety goals consistently, and how would we get  
18 additional tools, data, methods, or what comments do  
19 we have on the adequacy of the existing ones? Do we  
20 have anything to add to that?

21 (No response.)

22 Okay. Now I guess we will move on into  
23 the fun stuff -- the safety goals. The first question  
24 Bob and Dennis had up on their slides, and it is just  
25 what are your general thoughts about the value of and

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the need for safety goals? This is something that the  
2 Commission asked us to look at.

3 We are looking for feedback on whether we  
4 should or should not do it, and what is the value.

5 (No response.)

6 Where did you guys go for lunch?

7 MR. KOKAJKO: Pat, I notice that Felix  
8 Killar of NEI is here. He missed our morning program,  
9 and I think I see Dr. Judith Johnsrud here this  
10 afternoon. I'm not sure if you all have had a chance  
11 to look over the material yet or not.

12 It would be interesting to have your views  
13 on what you think might be appropriate in this area.

14 DR. RATHBUN: We can come back to you  
15 later, but if you want to speak now, that's fine.  
16 I'll give you my microphone.

17 QUESTION: I apologize for being unable to  
18 be here this morning. It's a very long trip and there  
19 were problems en route.

20 Judith Johnsrud, I am today representing  
21 Sierra Club and Pennsylvania Environmental Coalition  
22 on Nuclear Power.

23 I don't think it's possible to  
24 overemphasize the need for both safety goals and  
25 meeting those goals in every possible way. I found

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 myself thinking, as we all have, far more seriously in  
2 the past month and a half about safety needs with  
3 respect to risk assessment. Very frankly, although  
4 you have all been working on this issue now for at  
5 least a couple of years, I suspect that in the heart  
6 of hearts, each one of you is wondering if, in fact,  
7 we have thought seriously enough about what  
8 constitutes adequate risk assessment with respect to  
9 the management and control of radioactive materials  
10 and waste.

11 I recall attending a session sometime  
12 earlier this summer, I think it was, at which some of  
13 the discussion centered on the weight to be given to  
14 various incidents that are required to be reported to  
15 the Agency by its licensees and, as I recall, a  
16 private organization gave its approach which  
17 evidently, from the discussion, had been accepted by  
18 the Agency for the determination of the categories of  
19 significance for reported events upon which, in turn,  
20 to base risk analyses, among other uses.

21 And as I remember, those items that were  
22 reported most frequently were given a top category of  
23 concern whereas the infrequent events were to be given  
24 lesser consideration in regulatory control, and I  
25 think we all now have to consider much more seriously

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 the consequences of highly improbable events in making  
2 any kind of risk analysis.

3 I don't know if that really relates to  
4 your original question here or not.

5 DR. RATHBUN: Thank you. Felix, are you  
6 going to add to this conversation, or are you going to  
7 wait?

8 QUESTION: Unfortunately, I was in another  
9 meeting this morning, so I was not able to participate  
10 in this morning's session. So just kind of talking  
11 off-the-cuff from my general perspective on the aspect  
12 of safety goals, yes, we certainly value safety goals  
13 and think there should be safety goals established.

14 When you look at developing of safety  
15 goals, looking at the information here in your  
16 handout, giving an implicit answer that you're going  
17 to have safety goals that are going to be different  
18 between reactors, material licensees, and maybe even  
19 different between different types of material  
20 licensees, I'm not sure if that's the right thing to  
21 do or the wrong thing to do.

22 Safety goals are to protect a member of  
23 the public, the workers, the environment, and things  
24 along that line, and you should have a different level  
25 for this instance versus that instance. Now, what you

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 look at -- and maybe going to what Judith was just  
2 saying -- is look at the risk analysis and see what  
3 type of risks there are for that safety goal being  
4 exceeded by various different entities, and establish  
5 the parameters, safety requirements, to make sure you  
6 stay within that risk. And so a safety goal is a  
7 uniform safety rule across the Agency, but the  
8 application is based on the risk of that safety goal  
9 being exceeded based on the particular application.

10 So, when you're talking about safety  
11 goals, I think that's kind of my perspective, and  
12 that's just off-the-cuff.

13 Just looking at some of the insights of  
14 things that you have in here, I think there's probably  
15 some good stuff in here. I think that probably, after  
16 I get a chance to look at it some more, I may have  
17 some additional ideas or suggestions you may want to  
18 look at. I just gave it a quick scan in the last few  
19 minutes, and it looked reasonable.

20 DR. RATHBUN: Thank you. If you have more  
21 comments as you get a little more time to look through  
22 it, please step right up.

23 Dennis, is this something you want to  
24 respond to? Oh, I'm sorry -- Melanie. Excuse me.

25 QUESTION: Melanie Galloway. On the topic

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 of safety goals, I guess I have a question. I want to  
2 follow up on a statement that Dr. Bari had made on  
3 safety goals, stating in general that they would not  
4 likely be met. And I guess I'm wondering about the  
5 basis for that statement. I want to understand it a  
6 little bit further because I would think that while an  
7 individual facility or licensee might not be able to  
8 meet a given safety goal, that in the aggregate we  
9 would expect the licensees that fit the same category  
10 and apply to that safety goal, would indeed meet that  
11 safety goal.

12 And if I can recollect correctly -- it's  
13 been a few years since I've been in the reactor arena  
14 -- but I had thought that that was the consensus of  
15 the way reactors were meeting safety goals, that one  
16 individual reactor might not meet a given safety goal  
17 but, in the aggregate, the entire community of  
18 reactors would indeed be expected to meet the safety  
19 goal. And so I was wondering if there could be some  
20 expansion on that statement.

21 DR. BARI: Okay. The idea of a safety  
22 goal, as we mentioned, it really should be an  
23 aspiration, something that usually exceeds your reach,  
24 you would like to ideally make that goal, but in the  
25 regulations you would have limits that -- criteria

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 that licensees would be required to meet.

2 In the power reactor area, think of the  
3 core damage frequency -- of course, that's a  
4 subsidiary objective that people tend to be familiar  
5 with and relate to. The number there is  $10^{-4}$  per year  
6 core damage, and some reactors meet that and other  
7 reactors do not, but the ones that do not meet them,  
8 are they unsafe? The answer is, I think not. But on  
9 the aggregate, you are probably right, that they tend  
10 to cluster around  $10^{-4}$ , or perhaps a little bit lower  
11 than that.

12 MS. GALLOWAY: Am I to understand that  
13 when you made your statement, you were referring to  
14 individual licensees?

15 DR. BARI: That's correct.

16 MS. GALLOWAY: But that necessarily, in  
17 the aggregate, that indeed a safety goal would attempt  
18 to be met. That would be the goal of having a safety  
19 goal, that the industry or the category of licensees  
20 on the whole would meet the safety goal.

21 DR. BARI: Right.

22 MS. GALLOWAY: Okay. Thank you.

23 DR. RATHBUN: Dennis?

24 DR. DAMON: This is Dennis Damon. I would  
25 like to sort of concur with what Felix Killar said

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 about the -- you know, you raised the question or  
2 issue of should safety goals be the same, or should  
3 they be different in different areas, or what. And  
4 this is something that both Brookhaven, other people  
5 and I have thought about, and Dr. Bari pointed out in  
6 one of his slides, he said -- I believe the title of  
7 the slide was something like Issues to Consider, or  
8 something like that, and in that slide it starts to  
9 get into this process.

10 The general idea that I have absorbed from  
11 all this is you are not really focused on the source  
12 of the risk so much as you are focused on the  
13 characteristics of the persons at risk. I will give  
14 you an example of some of the things that come into  
15 defining different goals in different areas.

16 One is chronic exposure versus accident.  
17 It's not clear whether the risk that would be  
18 acceptable as a safety goal would be the same in both  
19 cases because a chronic exposure is incremental. It's  
20 much more under the control of the individual who is  
21 getting the exposure. He gets his badge read every  
22 month. He knows what he is getting. To a certain  
23 extent, he is in control of what he is exposed to  
24 whereas an accident often is something less under  
25 one's control. It happens to you. And some people

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 might be willing to accept more risk if it's chronic  
2 than if it was an accident.

3 Another one is the issue of voluntary or  
4 involuntary risk. The most obvious one is the general  
5 public in the vicinity of a facility. When the  
6 facility is put there, it is not voluntary, they are  
7 exposed to that risk. It is put there and they are  
8 exposed to it whereas if you choose to work at the  
9 facility, then at least to that degree you are  
10 voluntary, and maybe, therefore, the risk might -- one  
11 argument is that if you are a worker, you should be  
12 willing to accept more risk than the person who had no  
13 choice.

14 Then there is the issue that Dr. Johnsrud  
15 alluded to, which is should acceptability of risk --  
16 should safety goals and the acceptable level of them  
17 -- should it be sort of flat with risk. In other  
18 words, the risk being the expected consequence or  
19 likelihood-x-consequence, that being -- say, we define  
20 a risk measure equal to likelihood integrated over  
21 consequences -- should that be the same if you're  
22 talking about high consequence events. In other  
23 words, I talk about two events. One is 10 times the  
24 consequences of the other, but it is 10 times less  
25 likely, so they have equal risk. Should the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 acceptable level of risk for those two different  
2 situations be the same? Some people say no. They are  
3 what they call "risk averse". They say you should  
4 avoid the high-consequence event even more than the  
5 low one, even though the risk is the same.

6 My own view on that is that there are  
7 situations -- it depends upon the measure of risk you  
8 are using, but if the measure of risk is the same, my  
9 own personal view is I'm not risk-averse. I say it  
10 doesn't matter if you kill ten people one at a time,  
11 or ten people at one time -- you know, I am not risk-  
12 averse. I say it should be flat. But it is an issue.  
13 Some people think it should be tilted, and you should  
14 avoid the high-consequence thing more.

15 Another one is benefit. Some situations  
16 are such that the person exposed to the risk is also  
17 the person who benefits from the device or the thing  
18 that has it. For example, the smoke detector in your  
19 home has a radioactive material in it, but you benefit  
20 from having that smoke detector in there. And so, in  
21 that case, the tradeoff -- there is actually a  
22 tradeoff between risk and benefit. This happens in  
23 the medical field, but we don't regulate that  
24 tradeoff. But in other situations, there's actually  
25 a tradeoff there. You accept this risk and you get

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 this benefit. So the level of acceptable risk might  
2 be different in that situation.

3 So, there's all these factors like that so  
4 that it doesn't -- what I'm trying to say here is that  
5 it doesn't really depend on the device or the thing  
6 which is causing the risk but, rather, the person who  
7 is exposed and the characteristics of them, the degree  
8 to which they control the risk, the degree to which  
9 the benefit from it, and factors like that. Those are  
10 the ones we are thinking about influence what is  
11 acceptable to them or not, but not what the source of  
12 the risk was.

13 MR. MUBAYI: Just to amplify on a couple  
14 of things that Dennis just alluded to, one was in the  
15 question asked by the gentleman about the fact of  
16 having a uniform approach to safety goals across the  
17 Agency, or at least in specific parts. I think one  
18 can have a uniform approach, but as Dennis alluded to,  
19 the risk metric that you would use might be different  
20 because it is influenced by the kind of activity that  
21 occurs.

22 The risk metric that we have, for example,  
23 in the reactors where there are two safety goals that  
24 have been around for about 15 years, one relates to  
25 the likelihood of prompt fatality, which is a very

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 large release of radioactive material, and the other  
2 relates to likelihood of latent cancer fatalities with  
3 the linear, no-threshold dose response can occur, any  
4 level of exposure. So the risk metric for facilities  
5 where you have small amounts of material, you are not  
6 likely to benefit very much by a prompt or early  
7 fatality goal because you don't have -- that's a  
8 threshold-dependent exposure, and you are not ever  
9 likely to get -- or you are not going to get a level  
10 of exposure, so the metric may be different, but we  
11 would still strive to have a uniform goal.

12 The other was the issue raised about the  
13 high-consequence, low-probability releases or  
14 accidents. Just to remind us, in the reactor arena  
15 where risk has been calculated for a long time and the  
16 risk studies done later, NUREG 1150 and so on, most of  
17 the regulation is devoted towards precisely preventing  
18 accidents that have a very low likelihood or frequency  
19 of occurrence, but have high consequences. Those  
20 really dominate the risk and that's where most of our  
21 regulatory attention is directed.

22 DR. RATHBUN: Okay. I'd like to move a  
23 little bit further now into the safe goals, and see if  
24 you all can suggest, in addition to what you've just  
25 heard, any other applications of safety goals and/or

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 quantitative health objectives in regulating reactors  
2 that we might want to consider as we develop these for  
3 NMSS, if anything would come to your mind that we have  
4 not addressed in the reactor arena.

5 And I don't know how familiar you are with  
6 Reg Guide 1.174, but are there any insights from that  
7 document that you might want to bring to our  
8 attention, or anybody on the panel want to bring up  
9 anything about those. Vinod.

10 MR. MUBAYI: It's a big discussion. I  
11 don't want to enter that arena here, but Reg Guide  
12 1.174 defines a process for doing risk-informed  
13 regulation, and I think one area that might be useful  
14 to look at is something that Joe Murphy alluded to in  
15 the morning, which is that when you come in for any  
16 kind of change to your current licensing basis, any  
17 kind of change that you want to make, and we do a risk  
18 evaluation and we evaluate the delta change in risk  
19 based on the proposal, then they have some suggested  
20 numbers for this delta change at which you will either  
21 accept it or you will reject it, or you will put it in  
22 a box for further re-examination, look at it more.

23 I think what might be useful here, if we  
24 move towards a risk-informed regulation, is to do some  
25 of these assessments where these delta changes to risk

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 would happen because of some action or the other, and  
2 see if the recommendations that are in Reg Guide 1.174  
3 would also work in this arena and would more or less  
4 be a feasible way to go about doing business because  
5 it is a process, and that describes the process. And  
6 I think we would have to make a few tests to see how  
7 it worked here.

8 DR. RATHBUN: Thank you. The next  
9 question is for NRC licensees, but I think there is  
10 only one here, maybe two. But, nevertheless, for NRC  
11 licensees, have there been cases where regulatory  
12 requirement seems unnecessarily burdensome? Could  
13 qualitative safety goals or quantitative objectives  
14 help identify equally safe alternatives?

15 Do you want to give that a try, Felix? We  
16 know you, see, so that's the downside.

17 QUESTION: Felix Killar. What's  
18 interesting, we always ask our members are there  
19 regulatory guides or regulatory requirements that are  
20 a burden, and we can help the NRC reduce them. And  
21 they come back and say, well, we're working with it.  
22 We haven't identified any. And, also, to the second  
23 point, typically, the licensee has the obligation or  
24 ability to provide whatever method or process they use  
25 to demonstrate the safety of that facility. There's

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 nothing that dictates that you have to use this  
2 method, or what have you, to demonstrate that  
3 application, that process. So, right now the licensee  
4 does have the ability to come in with various  
5 alternatives and come up with what they think is best.  
6 Now, they have to defend that accordingly, and so  
7 right now I would say the process isn't broke, so we  
8 don't need to fix it. I don't know if Dennis will  
9 agree with me on that.

10 DR. RATHBUN: Did you want to add anything  
11 to that question, Dennis, that maybe I didn't pick up?

12 DR. DAMON: No, I think, you know, we're  
13 just looking for feedback. That's -- I don't know how  
14 to put this -- this is kind of an example of screening  
15 criteria. This is another way of saying what the  
16 screening criteria are about. One way to characterize  
17 it is that it's a way for you to clarify what you're  
18 going to use the risk information for. Another way of  
19 putting it is, if you come to an area and you run down  
20 the screening criteria, and the screening criteria  
21 talk about things like burden reduction and staff  
22 efficiency, and if your answer to the question is,  
23 well, staff seems pretty efficient to me, the licensee  
24 doesn't consider what's going on burdensome. We have  
25 very high confidence that the risk is low enough, even

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1       though we don't have a number for it. Okay. Then the  
2       answer is, you don't need to do a risk assessment.  
3       There's no use for it. So, in other words, it's just  
4       like Felix said, this area is not broke so don't try  
5       to fix it, and that's what those screening criteria  
6       are all about, basically, is to do that. But if there  
7       had been a large audience, what we were fishing for  
8       here is where are some areas where people think they  
9       do have a burden, or that things could be improved.

10               DR. RATHBUN: All right. now let's shift  
11       to the other side of the equation and say, do you know  
12       of any materials or waste device, practice or facility  
13       where there is a question as to whether it is safe  
14       enough, or maybe too safe? So, let's take it from the  
15       other side now.

16               MR. KILLAR: Certainly, from the industry  
17       perspective, Revised Part 35 did not go far enough as  
18       far as reducing the burden. Certainly, for the  
19       diagnostic purposes, the risk to the patient has been  
20       minimal, and where the NRC -- I can't remember who  
21       mentioned this -- said that the NRC has no  
22       responsibility as far as the medical application. The  
23       NRC has extended itself into the medical application  
24       in Part 35, and they tried to back out with revision  
25       to Part 35. They have not accomplished that. So,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 certainly from the perspective of the medical  
2 community, Part 35 still has not achieved the end  
3 result that they felt is reasonable.

4 I might want to pick up something else --  
5 and, Dennis, help me out here a little bit -- going  
6 back to Reg Guide 1.174 and doing the risk analysis  
7 and stuff, we don't have the sophistication in our  
8 models and tools for our material licensees, in most  
9 cases, to do the type analysis that are done in 1.174  
10 for the reactors. We don't have the risk analysis.  
11 We don't have the firm numbers.

12 Most of our stuff is more from physical  
13 characteristics, processing, handling and techniques  
14 rather than statistical type data and what have you.  
15 And so it's kind of hard for us to use 1.174 in our  
16 industry either from the aspect of a fuel site  
17 facility, a Part 70 license, or even from a Part 35  
18 licensee. We don't have the baselines and risk  
19 analysis. Even for the Part 70 facilities, as we go  
20 through and do our integrated safety assessments, they  
21 are not going to give us those type PRAs that exist  
22 over on the reactor side. We're going to have what I  
23 would call qualitative type things rather than  
24 quantitative type numbers to demonstrate that we're  
25 comfortable with the safety of our facilities.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. RATHBUN: Thank you. That's really  
2 important feedback because I remember we were  
3 specifically directed by the Commission to take a look  
4 at that. Any other comments on this area -- too safe?  
5 Not safe enough?

6 QUESTION: Judith Johnsrud again. We have  
7 a continuing concern that there is insufficient  
8 attention given to combined impacts, if you will,  
9 particularly with respect to the impacts of low-dose,  
10 chronic low-dose irradiation upon the immune system.  
11 The subject remains in controversy in the radiation  
12 safety community. But in our view, there is public  
13 interest imperative to exercise what is generally know  
14 as the pre-cautionary principle which, in essence,  
15 says when in doubt, don't, and in this instance that  
16 would be, when in doubt, come down on the side of  
17 excessive safety and regulation as opposed to relaxed.

18 We are particularly concerned that the  
19 Agency still does not take into account the  
20 synergistic impacts between those doses attributable  
21 to a nuclear facility, and the relationship to other  
22 contaminants in the biosystem which, taken together,  
23 the multiple sources of potential hazard may be  
24 substantially greater for the individual recipient.  
25 These are not factored into standards, and we

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 certainly believe they should be, recognizing that  
2 these are very difficult studies to undertake and to  
3 ascertain with any exactitude.

4 DR. RATHBUN: Okay. This is a long  
5 question -- Dennis wrote it. Societal risk is  
6 typically measured a metric something like the  
7 population dose for a scenario times probability  
8 integrated over all possible scenarios for a facility,  
9 and that would be a measure of total risk.

10 What level of such societal risk for an  
11 application is clearly low enough?

12 The reactor safety goal compared the risk  
13 of reactors to the risk of other means of generating  
14 electricity. This model does not seem to be  
15 applicable to many cases in NMSS. What level of  
16 societal risk is clearly low enough? How low is low  
17 enough?

18 Dennis, did you want to tell them?

19 DR. DAMON: Well, I'm interested in what  
20 people may have thought about this. I mean, we do  
21 this thing in society -- that is, we have things out  
22 there like automobiles and all the other things that  
23 impose risks on other people, and you kind of have to  
24 look at the whole picture. In other words, what's the  
25 total risk from some facility, or allowing some type

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 of device or equipment to be used in society? The  
2 question then becomes, what level is appropriate?

3 It's obvious that there's kind of a risk-  
4 benefit tradeoff on a societal level going on there.  
5 We allow all kinds of things to go on in our society,  
6 but if you look at the total -- how do I put this --  
7 if you look at total accident fatalities in our  
8 country -- let's not get into other things, but just  
9 accident fatalities, there are relatively few compared  
10 to total deaths. It's something like 90,000  
11 accidental fatalities and, I don't know, 2.8 million  
12 people die every year. So, in a way, that's kind of  
13 a measure at the total level of how much risk our  
14 society accepts from all the stuff we do. But the  
15 question becomes, if you're talking about a particular  
16 thing, a facility or a benefit you're getting of some  
17 kind from something, and it has risk associated with  
18 it, is there some level at which the risk is clearly  
19 very, very low?

20 See, it's not like the -- the individual  
21 risk measure is easier to perceive there. What they  
22 do there is they compare it to your average risk of --  
23 say, there's a risk of accidentally being killed by the  
24 thing, then you can compare it to the risk of an  
25 individual being accidentally being killed in general,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 which is a low number, and compare the risk that they  
2 are undergoing due to whatever the thing is. But when  
3 you're talking about societally, you're adding  
4 everything up, and then the question becomes, what do  
5 you compare that to? And one possible answer is you  
6 compare it somehow to the benefit society gets from  
7 whatever this thing is.

8 Another answer is, you compare it to the  
9 total -- actually, the reactor safety goal people do  
10 this, too, but only qualitatively. They say risks of  
11 a nuclear reactor should be a small fraction of total  
12 societal risk. Well, that's comparing total-to-total,  
13 but I'm not sure that's going to be that useful when  
14 you go to some of the things that are in NMSS. And so  
15 we are looking for what do you compare the total  
16 societal risk to for a facility, and then say is this  
17 too high, or is it low enough, remembering that  
18 there's always this individual risk goal. And the  
19 individual risk goal will have -- presumably, you will  
20 be trying to meet that already.

21 So, supposing -- I'll give an example. Is  
22 waste -- it comes up in decommissioning and waste  
23 disposal. You have material that has some hazard  
24 associated with it, and it's either out there or it's  
25 in a waste facility, but you've already made a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 determination that the levels are low enough that no  
2 individual would ever get a significant dose out of  
3 it, they would all get very low dose, at the most.  
4 That's maybe true for that facility, but there's a  
5 difference between dumping that waste in Manhattan and  
6 dumping that waste in the desert in Utah. The  
7 difference is there's no people in the desert in Utah  
8 to get exposed to it. So, the societal risk would be  
9 very low whereas there are people in Manhattan, they  
10 will get the dose. So, even though in both cases the  
11 individual who gets the dose gets the same low dose,  
12 there's a big difference between those two situations.  
13 So, if we don't tell our regulatory agency that they  
14 need to reduce societal risk, then we're not following  
15 common sense here. So, I say there is a need to  
16 reduce societal risk. Then the question becomes, how  
17 far is far enough for societal risk? I'll ask it a  
18 different way. When do you think a societal risk is  
19 very low compared to what?

20 DR. RATHBUN: Felix?

21 MR. KILLAR: Basically, I think what  
22 you're talking here is philosophy versus actual  
23 technical numbers because there is no technical number  
24 that everybody will agree to. I could sit here and  
25 say that the risk of this operation, whether it be a

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 nuclear power plant, fuel cycle facility, or a  
2 hospital, has a certain amount of risk to me and I'm  
3 willing to accept that. Someone else will look at  
4 those same risks and say, no, they won't accept that.

5 And so, once again, for personal risk,  
6 different people have risk levels. Walt Schwenk's  
7 example, he thinks it's perfectly all right to jump  
8 out of a well-operating airplane and parachute down to  
9 the ground. I've never wanted to jump out of a  
10 perfectly-operating airplane, I'd rather ride that  
11 plane to the ground.

12 So, in the mind of the individual, it's  
13 what risk they are willing to accept and what risk  
14 they are not. But then when you start talking about  
15 societal risk, you are looking at society as a whole,  
16 and society is everybody in this room as well as  
17 everybody that's in this community, as well as  
18 everybody that's in this State, and then it goes to  
19 everybody across the country, and across the country,  
20 the perspective of the country provides what the  
21 societal risk will be. And they don't necessarily  
22 weigh one thing the same as everything else.

23 I know we've had a number of studies where  
24 we talked to people across the country about the risk  
25 of nuclear facilities versus the risk of an airplane,

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 or the risk of smoking, or things on that line, and  
2 when we've done numbers, like you suggested, and said,  
3 okay, this is the risk of crashing an airplane, this  
4 is the risk of dying from smoking, this is the risk of  
5 living next to a nuclear power plant, and you find  
6 that the risk of a nuclear power plant is the lowest  
7 amongst all those, they'll say, gee, I didn't realize  
8 the risk of flying was so hazardous, because it's  
9 something that they've done every day, that they were  
10 comfortable with, but if you look at the actual number  
11 and the risk value and stuff, you know, the numbers  
12 are considerably different. It's the perception of  
13 the individual of the risk, and it has nothing to do  
14 with the technical numbers of it. So, I don't think  
15 you can come up with a number for societal risk.  
16 Certainly, as an individual or as an organization, you  
17 can come up with a number you feel is supportive, and  
18 industry will come in and say, yeah, we agree with  
19 that, and Judith will come in and say that, well, it's  
20 a good number, maybe you need to add these things in  
21 to provide some additional levels of conservatism, and  
22 these are our perspectives, but it is up to the  
23 country as a whole to determine what they want to say  
24 is a societal risk.

25 I don't know if I've answered your

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 question or I've muddied up the waters more.

2 DR. JOHNSRUD: Your comments, Dennis,  
3 don't specifically list the difference between an area  
4 of low population and an area of high population  
5 density. From my training as a geographer, I would  
6 caution that there are many areas of low population  
7 that nonetheless are extremely dependent upon a scarce  
8 resource such as water, and the contamination of that  
9 very scarce resource is of perhaps a higher concern  
10 for the population within such an area.

11 And so there is a set of considerations  
12 there that I think all too often we tend to ignore,  
13 those of us who live in the humid East, you know,  
14 compared to those who live in a desert terrain, and we  
15 are quite happy to place undesirable objects for  
16 disposal in areas that are perceived to be low in  
17 population and therefore expendable.

18 There is one other factor. At a  
19 conference in Canada two or three years ago -- this  
20 was of nuclear waste regulators -- there was  
21 substantial discussion of the need for consideration  
22 of forms of life other than human beings. It is my  
23 understanding that DOE has undertaken substantial  
24 biota studies with respect to environmental management  
25 and cleanup, and perhaps they are occurring within the

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 NRC for consideration in your standard-setting. If  
2 so, I am not aware of it, and I would be delighted to  
3 hear that they are.

4 DR. RATHBUN: Okay. Do we have any other  
5 comments on this area? Those were good points.

6 (No response.)

7 I'm about to move on now to future plans,  
8 so at this point in time, I just want to make sure  
9 that everybody who has wanted to contribute to the  
10 material that we discussed earlier has had that  
11 chance.

12 (No response.)

13 All right. An issue of great importance  
14 to us as we move into Phase 2 is what are the areas  
15 that we should look at initially. Are there areas  
16 that come to your mind that we should immediately  
17 begin to work on or work on earliest?

18 DR. JOHNSRUD: Judith Johnsrud again. I  
19 think I've just named the ones that I believe the  
20 Agency very much needs to take into consideration,  
21 particularly the nonfatal, noncancer, low-dose impacts  
22 on human health. And the research is ongoing, and we  
23 are learning more and more about low-dose effects that  
24 have previously been able to be ignored.

25 The grand battle over the linear

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 hypothesis continues, but I really don't anticipate  
2 that it is likely to be abandoned in the near future.  
3 Is anybody nodding yes or shaking heads no up there?  
4 And, indeed, the time has come for examination of the  
5 synergies with other contaminants and the impacts.  
6 Until six or seven weeks ago, it didn't really  
7 seriously occur to many of us that we needed to  
8 consider the impacts upon the immune system from a  
9 radiation exposure with respect to the ability of a  
10 victim of, oh, anthrax or smallpox or plague, to be  
11 able to recover from that illness, but I rather doubt  
12 that we have very good data on such a matter which now  
13 is a reality among us.

14 DR. DAMON: Let me ask Dr. Johnsrud about  
15 the synergies thing. That does raise an interesting  
16 thing. I really do not, myself, know very much about  
17 chemical carcinogenesis, or whatever you call it, but  
18 is there an issue there of -- I mean, my impression is  
19 this, that there -- like, you take radiation, say, low  
20 linear energy transfer radiation, the effect of that  
21 is basically the same in -- how do I put it -- is  
22 basically -- produces one type of effect on the cells  
23 and produces oxygen radicals and so on and so forth,  
24 that you can determine the type of effects that those  
25 things have. But suppose you have two things, you

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 have a chemical which is different from the oxygen  
2 radicals that the radiation produces, and you have  
3 radiation. Are you saying that there's like the kind  
4 of mutations or other effects that the particular  
5 chemical might be synergistic with the ones that the  
6 radiation does, so that you get somehow -- you know  
7 what I mean -- that kind of -- is that what you're  
8 talking about?

9 DR. JOHNSRUD: You're asking "the"  
10 research question. Yes, indeed. And it's not easy to  
11 assess, there's no question about that. But,  
12 nonetheless, we do live in a sort of soup of a great  
13 variety of contaminants that are released into the  
14 biosystem that may, indeed, have variable impacts upon  
15 various sectors of the total exposed population, the  
16 very young as opposed to the healthy adult standard  
17 man, for instance.

18 I really don't believe that the Agency, or  
19 your brother agencies, have gone very far in such  
20 assessments, but the consequences to human health, or  
21 to the survival and the health of other flora and  
22 fauna upon which, incidentally, we may depend for our  
23 human survivability. All of these matters that are  
24 legitimately of need to be examined by the Agency and  
25 taken into consideration.

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. DAMON: That reminds me of something,  
2 and don't quote me on this, but if I remember, the  
3 BEIR reports, when they were trying to estimate cancer  
4 caused by radon, I believe somebody asserted that  
5 actually what they were determining was the  
6 synergistic effect between smoking and radon exposure.  
7 It was actually most of the risk that was occurring  
8 were in the smokers, and it was some kind of synergism  
9 was going on there.

10 DR. JOHNSRUD: That relationship between  
11 cigarette smoking on the part of uranium miners and  
12 the radon from the mines, as I recall, was utilized in  
13 order to disallow compensations early on, and -- oh,  
14 gosh, this goes back to perhaps back in the Lyndon  
15 Johnson Administration -- when that concern was set  
16 aside as an excuse for not setting more restrictive  
17 standards for the workers.

18 Now, subsequently -- or about the same  
19 time, actually -- the work was done on cigarette  
20 smoking and polonium-210 by, as I recall, Ted Radford,  
21 who has died just this past week, who had chaired  
22 BEIR-3, and that relationship, I believe, has held in  
23 the literature since.

24 DR. RATHBUN: Do you have anymore  
25 questions for her, Dennis?

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 DR. DAMON: No.

2 DR. RATHBUN: All right. At this point --

3 MR. KILLAR: Could I just make one  
4 statement? There has been some work done, very much  
5 limited, but one of the issues that has come up is a  
6 question of hormesis (phonetic). Radiation as well as  
7 a damaging agent has been limited to and possibly  
8 synergistic effects, as Dr. Johnsrud has indicated,  
9 and also provide an enhancement to the immune system  
10 and improved the immune system, some aspects of it.  
11 This has been questioned, this has been challenged,  
12 and it continues to be questioned and challenged. So,  
13 it's not something that is greatly supported, but also  
14 at the same time there is enough peer evidence to  
15 indicate that there is certain advancements and  
16 improvements due to -- things along that line.

17 We have looked -- there have been some  
18 studies looking at the synergistics effects of various  
19 chemicals and radiation. The problem is that down in  
20 the levels that we're talking about, these low levels  
21 of radiation and also low levels of the chemicals,  
22 it's hard to trace something determined through  
23 epidemiology studies that the effects are there or  
24 there are sporaze, or whether they are true or false  
25 positives, things along that line. There just isn't

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 enough, and we don't have the techniques to  
2 necessarily demonstrate all the things that you need  
3 to demonstrate to say definitely one way or the other.

4 DR. JOHNSRUD: If I may follow through,  
5 the Department of Energy has undertaken a fairly  
6 substantial research project on low-dose impacts,  
7 which I assume that all of you are acquainted with,  
8 and my reading of the interim reports of their  
9 researchers mostly cellular and molecular studies are  
10 not epidemiological, are confirming that far more work  
11 on low-dose impacts is needed, but I haven't seen a  
12 great deal of confirmation in that research of  
13 hormesis. There may be some instances in which an  
14 irradiation is, indeed, beneficial as we consider it  
15 to be in medical practice certainly, but that takes us  
16 back to the fundamental of radiation protection, of  
17 the opportunity for choice, for decisionmaking such  
18 that the risk will be less than the benefit, and that  
19 is an individual choice in each instance.

20 DR. RATHBUN: Okay. If there are no other  
21 questions, I think I'm going to turn this thing back  
22 now to Lawrence, but I'll sit right here with you.

23 MR. KOKAJKO: I'd like to thank all of you  
24 for participating today. We view feedback from our  
25 stakeholders, both public and the NRC, to be a very

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 important component of implementing the case study  
2 plan. Your input regarding the case studies and  
3 development of safety goals is important to  
4 understanding where we are on-track and what areas we  
5 may need to give further thought. And I have  
6 appreciated your views in regard to the screening  
7 process, its guidance development, regulatory process  
8 improvements, including tools, methods and data,  
9 commentary, and your thoughts on safety goal  
10 development.

11 I don't think I have heard anyone negate  
12 or otherwise dismiss the idea of developing safety  
13 goals, that you think they could be feasible and that  
14 they may be worthwhile to pursue. And I did hear some  
15 things for process improvements that we may want to  
16 consider, and we will look into that in our next  
17 steps.

18 I also didn't hear today, this morning as  
19 well as this afternoon, that we should cease this  
20 activity, that there is some value to be gained from  
21 doing it, and that we should continue this effort.

22 Before I finish today, I want to note that  
23 we did start this back in April of 2000, and as we  
24 assess where we need to go in regard to this work  
25 toward the end of this year and next, we hope to have

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 future meetings as we progress.

2 If you signed the attendance sheet -- and  
3 I encourage you to do so if you have not -- we can  
4 contact you and invite you to any future meetings that  
5 we might hold.

6 We hope to issue a final case study report  
7 as an integrated report, as well as the screening  
8 considerations guidance document at the end of the  
9 calendar year. However, I should point out that  
10 recent events may mandate a more drawn-out schedule  
11 than what we originally thought, and we will have to  
12 adjust our activities and schedules as Agency  
13 priorities dictate, especially in light of September  
14 11th.

15 As I mentioned in my opening remarks, we  
16 are interested in feedback on your views of how this  
17 meeting went and any feedback forms you fill out we  
18 would greatly appreciate hearing from you. They are  
19 in the lobby area, and you can either mail them in or  
20 provide them to a member of our Risk Task Group.

21 I'd also like to thank today those  
22 involved in coordinating and presenting this meeting  
23 today, especially our Deputy Director, Margaret  
24 Federline, our Facilitator, Dr. Patricia Rathbun. I'd  
25 also like to note that the administrative support

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701

1 provided by Jessica Shin, who is a third-year chemical  
2 engineering student at the University of Maryland, has  
3 been outstanding, I might add. Without her help, we  
4 wouldn't have been able to put this on. Also, Marissa  
5 Bailey, Raeann Shane, James Danna, James Smith, Dr.  
6 Dennis Damon, and Dr. Robert Bari, and Dr. Vinod  
7 Mubayi, and our newest oldest member of the Risk Task  
8 Group, Christiana Lui.

9 I'd also like to thank our subject matter  
10 experts who have supported us throughout the past  
11 year: Jack Parrot, Andrew Persinko, Mike Layton, John  
12 Lusher, Brian Smith, Earl Easton, and Dr. Mahendra  
13 Shah, Michael Waters, and I hope I haven't forgotten  
14 anyone else. Your help was invaluable and we do thank  
15 you.

16 I'd like to seek your comments one more  
17 time.

18 (No response.)

19 Hearing none, hearing no further comments  
20 or questions, this meeting is adjourned. Thank you  
21 very much for your participation.

22 (Whereupon, at 2:40 p.m., the meeting was  
23 concluded.)

24

25

**NEAL R. GROSS**

COURT REPORTERS AND TRANSCRIBERS  
1323 RHODE ISLAND AVE., N.W.  
WASHINGTON, D.C. 20005-3701